A differentiation method for obtaining large numbers of cells by chopping 3D organoids prepared from human pluripotent stem cells

The 3D organoid differentiation method addresses reproducibility and yield limitations in two-dimensional cultures by patterning and chopping 3D organoids, producing stable, functionally superior midbrain dopamine neurons with astrocytes for Parkinson's disease treatment and drug screening.

JP7587584B2Active Publication Date: 2024-11-20CORESTEM CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022542468
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-01-13
Publication Date
2024-11-20
Estimated Expiration
2040-01-13

AI Technical Summary

Technical Problem

Existing methods for differentiating human pluripotent stem cells into midbrain dopamine neurons for Parkinson's disease treatment face issues of reproducibility, unstable expression of midbrain-specific factors, absence of astrocytes, and limited neuron yield, particularly in two-dimensional cultures.

Method used

A method involving the patterning and chopping of 3D organoids derived from human pluripotent stem cells to enrich target cells, allowing for the stable differentiation of large quantities of terminally differentiated cells, including midbrain dopamine neurons and astrocytes, which can be used for cell therapy and drug screening.

Benefits of technology

The method enables reproducible, large-scale production of functionally superior midbrain dopamine neurons with stable expression of critical factors and the presence of astrocytes, enhancing therapeutic efficacy and drug screening capabilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587584000018
    Figure 0007587584000018
  • Figure 0007587584000019
    Figure 0007587584000019
  • Figure 0007587584000020
    Figure 0007587584000020
Patent Text Reader

Abstract

The present invention relates to a method for patterning and chopping 3D organoids prepared from human pluripotent stem cells, culturing stem cells or progenitor cells, and inducing their differentiation to obtain a large number of terminally differentiated cells.Compared with cells differentiated by conventional methods, the obtained cells in large quantities exhibit significantly superior effects in terms of reproducibility, stability, and functionality, and are therefore expected to be very useful for cell therapy or screening of therapeutic drugs.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a differentiation method for dissociating and chopping 3D organoids prepared from human pluripotent stem cells to obtain large amounts of terminally differentiated cells.

[0002] [Background technology] Parkinson's disease is a neurodegenerative disease caused by the loss of dopamine neurons in the substantia nigra of the midbrain. Since the affected area and affected cells are clearly defined, it is known to be the most suitable disease for stem cell transplantation.

[0003] Cell therapy for Parkinson's disease requires the differentiation of stem cells into human midbrain dopamine neurons (mDA neurons), and differentiation methods have been developed over a long period of time to differentiate human pluripotent stem cells (hPSCs), human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) into mDA neurons [3D brain Organoids derived from pluripotent stem cells: promising experimental models for brain development and neurodegenerative disorders, Journal of Biomedical Science (2017) 24: 59]. However, there are several problems in using these differentiation methods for clinical applications, including:

[0004] The first is the problem of reproducibility. The existing 2D methods are very complicated, so they have not been fully reproduced in other laboratories. In addition, the existing 2D methods are only applicable to some pluripotent stem cell lines, such as H9, and in all of the developed methods, H9 was used for development, and differentiation into midbrain dopamine neurons did not occur sufficiently in some other pluripotent stem cell lines.

[0005] The second is the problem of stable expression of midbrain-specific factors. Midbrain-specific factors, such as Nurr1, Foxa2 and Lmx1a, are known to be crucial for the survival, function and maintenance of midbrain dopamine neurons, and thus are closely related to the ability to treat Parkinson's disease after transplantation. Due to this fact, the recently developed protocols for differentiating hPSC-mDA neurons have all been developed with a focus on the expression of midbrain-specific factors in midbrain dopamine neurons. However, the expression of these midbrain-specific factors is very unstable and is easily reduced after long-term culture or transplantation of midbrain dopamine neurons. Therefore, in transplantation of cells differentiated by the methods developed to date, only the expression of some midbrain-specific factors (mainly Foxa2) has been shown in transplanted midbrain dopamine neurons.

[0006] The third problem is that astrocytes do not exist in cultures of differentiated mDA neurons. Astrocytes are not included in cultures of differentiated mDA neurons by the methods developed to date. Astrocytes are cells that are responsible for enhancing the survival and function of neurons, such as mDA neurons, and are essential for maintaining normal survival and function of neurons in actual brain tissue. In addition, astrocytes are necessary to maintain the expression of midbrain-specific factors in mDA neurons.

[0007] Finally, there is a problem regarding the amount of neurons that can be obtained by differentiation of neurons. The dopaminergic neuron differentiation methods developed to date directly induce differentiation into neurons without the neural stem cell stage that allows proliferation in the midbrain, so there is a limit to the amount of terminally differentiated neurons that can be obtained by one differentiation.

[0008] [Detailed Description of the Invention] [Technical Issues] Therefore, the inventors focused their research efforts on the fact that three-dimensional culture using organoids realizes an environment closer to the actual brain environment than two-dimensional cell culture, enabling healthy cell culture. Each organoid, which can sufficiently contain target cells, i.e., progenitor cells or stem cells, was patterned to prepare a cell population with the desired fate to multiple cell populations (enriched target cells). This organoid tissue was chopped and the progenitor cells or stem cells were cultured. Other techniques are applied to the development of differentiation methods by patterning cells by two-dimensional culture methods and quantitatively securing them, or by borrowing only the intermediate stage of three-dimensional spheres to obtain cells, but in the present invention, cells in the desired state are sufficiently enriched by properly culturing through organoids in their complete form (target cells). Therefore, it was confirmed that each cell isolated by the present invention was functionally superior by going through a complete three-dimensional artificial brain region called organoid compared to other existing techniques.

[0009] [Problem Resolution] Therefore, it is an object of the present invention to provide a method for patterning and chopping 3D organoids prepared from human pluripotent stem cells, culturing stem or progenitor cells and inducing their differentiation to obtain large quantities of terminally differentiated cells.

[0010] In addition, another object of the present invention is to provide a cell therapy agent containing the differentiated cells obtained by the above method as an active ingredient.

[0011] In addition, another object of the present invention is to provide a drug screening method using the differentiated cells obtained by the above method.

[0012] [Effects of the invention] In the present invention, terminally differentiated cells can be differentiated in large quantities by chopping the prepared 3D organoids, isolating stem cells or progenitor cells from the organoids, and culturing and expanding the stem cells or progenitor cells, so that a large amount of cells can be obtained at once. For example, when the method of the present invention is applied to mDA neuron differentiation, differentiation can be easily induced without cell line dependency or batch-to-batch variation, so that the method of the present invention can be easily reproduced in other laboratories. In addition, when the mesencephalic neural stem cells differentiated by the present invention are transplanted into Parkinson's disease, a series of Nurr1, Foxa2, Lmx1a, etc., which are known to be extremely important for the survival, function and maintenance of mDA neurons, are faithfully expressed in the transplanted mDA neurons, and thus the therapeutic effect of cell transplantation is significantly improved. In addition, astrocytes, which are cells responsible for enhancing the survival and function of neurons, also exist together with mDA neurons, and thus astrocytes are thought to protect mDA neurons, enhance the function of mDA neurons, and contribute to the enhancement of cell transplantation therapy during transplantation.

[0013] Therefore, the differentiated cells obtained in such large quantities (including cerebral astrocyte precursor cells, midbrain astrocyte precursor cells, midbrain dopaminergic neural stem cells, hypothalamic neural stem cells, etc. in addition to mDA neurons) can be used as cell therapeutic agents or can be used to screen drugs that can be treated together with the cells. [Brief description of the drawings]

[0014] [Figure 1A]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1B]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1C]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1D]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1E]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1F]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1G]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1H]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1I]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1J]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1K]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 1L]Methods for preparing mesencephalic organoids and extracting mesencephalic neural stem cells from mesencephalic organoids are shown. [A: Diagram showing how to grow neural stem cells from organoids with bFGF in a 2D environment to obtain neural stem cells. B and C: Confirmation of the expression of mesencephalic markers (OTX2, FOXA2, LMX1A, PAX2 and PAX5) and neural stem cell markers (SOX2, NESTIN and KI67) by fluorescent staining of mesencephalic neural stem cells expanded from organoids for 2 weeks. D: Calculation of the proliferation rate of mesencephalic neural stem cells expanded from organoids. PDL (population doubling level, bars) and cumulative PDL (lines). E to G: Confirmation of accurate differentiation of mesencephalic dopamine neurons after inducing differentiation of mesencephalic neural stem cells expanded from organoids for 12 to 15 days. Confirmation of midbrain-type markers (FOXA2, LMX1A, NURR1 and EN1) along with dopamine neuron marker (TH), and fully mature neuron differentiation markers (AADC, SYPT and DAT). F: Confirmation of expression percentage for neurons differentiated from 2D neural stem cells. G: Confirmation that the protocol was stably realized when using various human embryonic stem cells and induced pluripotent stem cells. H: Confirmation of stable differentiation success rate of organoid-derived neural stem cell differentiation technique against 2D differentiation method. (When implementing each method, the success criteria are >70% (>30%) TH+ of MAP2+ neurons and >70% (>20%) NURR1+ of TH+ mDA neurons). I-L: Organoid-derived neural stem cell differentiation protocol can more stably inhibit cell death and differentiate cells. Programmed cell death (senescent) as EthD-1+ dead cells (I), cleaved caspase 3+ dead cells (J), using FACS-Annexin+ / PI+ cell counts (K), and β-galactosidase stained cells (L). *P = 0.0045 (I), 0.02 (J), 0.008-0.044 (L), 0.003 (K), n = 3 independent experiments, one-tailed Student's t test. Scale bars 25 μm (J), 50 μm (B, E, I, and K)]. [Figure 2A]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA-sequencing data, therefore a heatmap analysis was performed (J). [Figure 2B]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA-sequencing data, therefore a heatmap analysis was performed (J). [Figure 2C]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA sequencing data, therefore a heatmap analysis was performed (J). [Figure 2D]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA-sequencing data, therefore a heatmap analysis was performed (J). [Figure 2E]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA sequencing data, therefore a heatmap analysis was performed (J). [Figure 2F]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA sequencing data, therefore a heatmap analysis was performed (J). [Figure 2G]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA-sequencing data, therefore a heatmap analysis was performed (J). [Figure 2H]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA-sequencing data, therefore a heatmap analysis was performed (J). [Figure 2I]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA sequencing data, therefore a heatmap analysis was performed (J). [Figure 2J]Analysis of transcriptional regulation (transcriptomic signature) of organoid-derived neural stem cells [A and B: Analysis of differences in regulation of previously reported transcription factors by bulk RNA sequencing of RNA of prepared midbrain-like organoids (MLO), organoid-derived neural stem cells (Og-NSC) and 2D-derived neural stem cells (2D-NSC), as well as midbrain tissue during development (public transcriptome transcriptional dataset of prenatal midbrain), adult striatum (adult substantia nigra) with dopaminergic neurons, adult cerebral cortex (cortex) and hindbrain. A: Spearman correlation plot. Analysis of DEGs (differentiation expressed genes) of 2D neural stem cells and organoid-derived neural stem cells. B: PCA (principal component analysis) of bulk RNA sequencing data. PCA scores are centered on 1,000 genes with the largest difference in expression. C-G: Analysis of transcriptional regulation in organoid-derived neural stem cells (Og-NSCs) and 2D-derived neural stem cells (2D-NSCs) by single-cell RNA sequencing. (13,793 and 12,166 cells were analyzed, respectively.) C: t-SNE (t-distributed stochastic neighbor embedding) maps are colored based on the data. D: Three separate k-means clustering by t-SNE projection (Loupe Cell Browser ver.3.0.1, 10X Genomics,Inc.). Analysis of Og- and 2D-NSCs are analyzed in Venn diagrams (below), respectively. E: Hierarchical clustering analysis of 40 overexpressed genes in each cluster compared to other groups. F: Top-ranked GO based on overexpressed genes in each group (UMI>1, log2FC>0.5, P<0.05, DAVID). G, Representative gene expression differentially regulated compared to other groups. Data are represented by color depth (log2 expression (UMI). F-H, DEGs showing more prominent expression (vs. 2D-NSC, log2FC>1, padj<0.01) in Og neural stem cells compared to 2D neural stem cell analysis using bulk (H) and single-cell RNA sequencing datasets (I).The expression of “cell-cell adhesion” was increased in both bulk- and single-cell RNA sequencing data, therefore a heatmap analysis was performed (J). [Figure 3A]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3B]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3C]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3D]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3E]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3F]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3G]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3H]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3I]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3J]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3K]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3L]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3M]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3N]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3O]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3P]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3Q]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3R]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 3S]Results obtained by analyzing the maturity and functionality of Og-NSCs and dopaminergic neurons in terms of mitochondrial function and results showing differences in neuronal maturity in the two groups are shown. In conclusion, we show that Og-NSCs can be differentiated to a healthier and more mature morphology compared to previously generated NSCs. [A-F: Neurons derived from organoid neural stem cells (Og-NSCs) maintain mitochondria in a healthy state even under mitochondrial toxin experiments. A: STRING analysis of mitochondrial factors overexpressed in Og-NSCs (vs. 2D-NSCs). B: Analysis of mitochondrial synthesis (mitochondrial biogenesis (MitoTimer)). *p=0.0000005 (48 h), 0.024 (24 h), n=4 cultures. C: Mitochondrial ROS (MitoSox) and D, mitochondrial membrane potential (JC-1). *p=1.9e-46, independent culture, 310-314 cells (C); p=3.5e-21, results of 283-311 cell analysis from three or more independent experiments (D), Student's t-test. E, F, Analysis of survival of dopaminergic neurons differentiated under mitochondrial toxin treatment for 4 days. Cell survival / death (E) and analysis of dopaminergic neuron length (F). ROT, rotenone; CC, cccp; HO, H2O2 *p=0.013-0.165 (E), p=0.000032-0.11 (F) n=3, Student's t-test. G-P: Analysis of dopaminergic neuron maturity and functionality. G, Heatmap analysis of Og-NSC-specific (vs. 2D-NSC) expression genes. H, Highly mature dopaminergic neurons derived from Og-NSCs, typically analyzed by the Neurolucida analysis program. J, Length analysis of dopaminergic neurons from 12 days of differentiation. Length of TH+ fibers from 23–58 cells / culture was measured. *p=0.013, n=7 (Og), 3 (2D) independent cultures, t-test. I, K, Analysis of dopaminergic neuron synapses. The number of neurons actually forming synapses was analyzed by synaptophysin staining.(27-43 TH+ fibers / culture) *p=0.03, n=5 cultures per group. L-O, Analysis of Ca2+ influx based on neuronal function. L, 1AP-producing neurons from Og-NSCs and 2D-NSCs were observed. Og-NSCs (red) and 2D-NSCs (black). Arrows indicate 1AP points. M, Mean 1AP response amplitudes: [Ca2+ influx]Og=0.60±0.09 (n=10), [Ca2+ influx]2D=0.16±0.02 (n=12). N, Trace of Ca2+ influx upon stimulation. O, Mean Ca2+ influx kinetics during 100AP response: [τ of Ca2+ influx]3D=0.85 s±0.11 (n=10), [τ of Ca2+ influx]2D=2.35 s±0.43 (n=12). *p=0.0009 (M), p=0.005 (O), Student's t-test. P, presynaptic DA secretion. DA levels were measured as dopamine secretion at days 13–15 of differentiation in culture with conditioned medium for 24 h. KCl depolarization was induced for 30 min. *p=0.0006–0.0009, n=4 (Og), 5–6 (2D) independent cultures. Q, R, Ability of Og-NSCs to differentiate into astrocytes. An astrocyte progenitor population was observed in cluster 1 of single RNA sequencing (Q). The CD44+ astrocyte progenitor population was included in the neural stem cell population (R) and differentiated after differentiation to form astrocytes (GFAP) together with dopaminergic neurons (TH) (S). This was observed in the Og-NSC group but was rare in the 2D-NSC group. *p = 0.004 (R), p = 0.0003 (S), n = 3–4 independent cultures. Scale bars, 10 μm (I), 25 μm (B,R), 50 μm (C,D,S), 100 μm (H)]. [Figure 4A]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4B]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4C]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4D]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4E]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4F]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 4G]When observed in a model of α-synucleinopathy, which is a biological characteristic of Parkinson's disease, the neural stem cells induced by the method of the present invention show that α-synuclein, the cause of severe Parkinson's disease, is not sufficiently spread, and therefore it can be said that it is advantageous when used as a cell therapy for Parkinson's disease. [Neurons induced from organoid-derived midbrain type neural stem cells (Og-NSCs) were observed to have relatively less α-synuclein spread. Neurons may be more resistant to the α-synuclein disease environment. A-D, Observation of the characteristic that α-synuclein penetrates less into neurons. Og-NSCs (vs. 2D-NSCs). A, Dual chamber system that allows observation of the transfer of α-synuclein between cells. B: α-synuclein intensity (GFP) was compared in 768 (Og) treated cells and 740 (2D) treated cells. *p=0.000004. It was observed that α-synuclein penetrated relatively less into Og-NSCs. C-F: When α-synuclein oligomerization, which may be the cause of Parkinson's disease, was induced by an overexpression system using a virus, the p129-α-synuclein level, which may be the cause of pathology, was observed to be relatively low, especially in Og-NSCs. (C) Western blot analysis of α-synuclein oligomers after induction of viral overexpression (left) or optional PFF (preformed α-synuclein fibrils) treatment (right). It was observed that α-synuclein oligomers, which may be the main cause of Parkinson's disease, occurred less in Og-NSCs (D) and Bi-FC systems (E, F). Bi-FC green-expressing inclusions were observed relatively less in Og-NSCs. This indicates that the same amount of α-synuclein has a lower probability of aggregation and pathogenesis (F). *p=0.001 (C) and 0.02 (F), n=3 independent experiments. G, Histological analysis was performed after transplantation of Og-NSCs (left hemisphere) and 2D-NSCs (right hemisphere) into PFF-α-synuclein model animals, respectively. The animals were induced with PFF and α-synuclein AAV virus for 2 weeks to induce Parkinson's disease model, and the animals were sacrificed 1 month after transplantation of each cell.Relatively less malignant α-synuclein (p129-α-synuclein) was observed at the Og-NSC transplantation site, along with healthy dopaminergic neurons. Scale bars, 50 μm (B, C, F), 100 μm (G)]. [Figure 5A] In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5B]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5C]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5D]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5E]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5F]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5G]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 5H]In vivo prediction studies of various aspects of outcomes that may appear after transplantation of Og-NSCs are shown. [A: Analysis of the expression of factors reported as important factors for successful dopamine neuron transplantation by single-cell RNA sequencing data showed that Og-NSCs showed relatively high expression (vs. 2D-NSCs). The result values ​​are expressed as color density. They are expressed as log2 (represented by unique molecular identifier (UMI) values) (left) and the average ratio of log2 Og / 2D expression values ​​(right). B: Images observed by two-photon fluorescence endomicroscopy by transplanting pSyn-GCaMP6-expressing neurons into the dorsal striatum (upper panel). ROIs (regions of interest) of different colors of GCaMP6 fluorescence are circled in the upper image of the figure (B, lower panel). C-F: Action potential firing and synaptic transmission at the transplantation site derived from Og-NSCs. Og-NSCs, differentiated from PDll1-GFP-hESCs and expressing neural stem cell fluorescence, were transplanted into the striatum of hemi-parkinsonian model animals. Whole-cell patch clamp recordings from brain slices of animals 1.5 months after transplantation. Intrinsic excitability was observed by dedifferentiation current injection of transplanted GFP+ cells (C), and sEPSCs were recorded at -70 mV holding potential (D). The mean amplitude (E) and frequency (F) of sEPSCs from Og-NSC-derived transplanted sites were compared with those of normal cells from non-transplanted sites (left side). n=5 (grafts) and 4 (control, no lesion) from two rats. G, H: 18F FP-CIT DAT binding was analyzed by MRI and PET scans after 5 months of transplantation of Og-NSCs into 6-OHDA Parkinsonian-induced animals. *p=0.021, n=8 (grafts) and 5 (control, lesioned). T: Implantation site. Scale bar, 200 μm. [Figure 6A]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6B]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6C]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6D]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6E]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6F]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6G]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6H]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6I]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6J]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6K]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6L]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6M]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6N]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6O]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 6P]The results observed after transplantation of Og-NSCs into actual Parkinson's disease model animals are shown below. [Og-NSCs were transplanted into 6-OHDA-induced hemiparkinsonian model rats (A-O) and also into Philippine monkeys (P). A-C: Behavioral analysis of Parkinson's disease animals after transplantation. A: Six months after transplantation, amphetamine-induced rotation scores were observed. At the start, 14 Parkinson's disease model animals were transplanted with Og-NSCs, and amphetamine-induced behavioral recovery scores were analyzed monthly for 1-6 months after transplantation. When 6 animals had >60% of behavioral recovery scores in 1-4 months, the animals were sacrificed for analysis. Recovery is expressed as a percentage (%) based on the behavioral score analysis data before transplantation. Seven animals in the saline transplant group were used as the control group. (Analysis of sham (PBS-injected) controls (n=7) was *p=7.8e-10-0.037, one-way ANOVA.) The stage adjustment test was performed over 6 months after transplantation as another behavioral experiment in the Og-NSC transplantation animal model, *p=5.58e-07-0.0006, one-way ANOVA, post hoc Tukey analysis (B). In addition, the cylinder test was performed, *p=1.63e-08-0.000424, one-way ANOVA, post hoc Tukey analysis (C) (n=8). D: In the Og-NSC transplantation animal model, 6 months after transplantation, the morphology of dopamine neurons was observed by neurite tracing (Neurolucida) images, and the results confirmed that they were differentiated into mature morphology. E-O: Histomorphological analysis was performed by fluorescent staining. E-G: Confirmation of TH+ / FOXA2+, TH+ / LMX1A+, TH+ / NURR1+ dopaminergic neurons at the transplantation sites. The enlarged images at the bottom confirm that the transplanted dopaminergic neurons are true midbrain-type neurons. I: Fluorescent staining with midbrain-type factors confirmed the expression % at the transplantation sites of 8 animals (13,697 TH+ cells were analyzed). L-P: The transplantation sites were calculated by volume (L), number (M), density (N), and body size (O) of TH+ neurons 6 months after transplantation (n=8 rats).P, One month after transplantation into adult Philippine monkeys (Macaca fascicularis), among the TH+ dopamine neurons, transplanted dopaminergic neurons were confirmed to express STEM121, indicating that the transplanted cells were derived from human cells, as well as transplanted dopaminergic neurons that expressed FOXA2 and NURR1 as midbrain-type markers. Scale bars, 50 μm (lower panels of E–G, lower panels of H, J, K, and P), 200 μm (upper panels of P), 500 μm (D–G)]. [Figure 7A] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7B] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7C]Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7D] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7E] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7F]Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7G] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7H] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7I]Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7J] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7K] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7L]Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7M] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7N] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7O]Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 7P] Generation and characterization of midbrain-like organoids from hPSCs. [A: Schematic of the experimental procedure to generate midbrain-like organoids. B–D, Phase contrast images of organoids over days in vitro (DIV). Scale bar, 200 μm. E–O: Representative immunofluorescence images of neural structures formed in organoids. Organoids were cryosectioned in vitro on the indicated days and stained with the indicated antibodies. V, ventricle; VZ, ventricular zone; IZ, intermediate zone; MZ, mantle zone; Scale bars, 100 μm (E–P), 200 μm (B–D)]. [Figure 8A] This shows that the maintenance of midbrain neural stem cells is efficiently improved by controlling the treatment time of FGF8, which is important for midbrain neurogenesis, by the method of the present invention [A: FGF8b treatment schemes of protocols A and B. B: RNA sequencing data for the expression of ventral midbrain (VM)-specific and hypothalamus-specific markers in organoid (Og)-NSCs calculated by two different FGF8b treatment schemes. C: Representative images of EN1+ / TH+mDA neurons induced by protocols A and B. Scale bar (50 μm)]. [Figure 8B]This shows that the maintenance of midbrain neural stem cells is efficiently improved by controlling the treatment time of FGF8, which is important for midbrain neurogenesis, by the method of the present invention [A: FGF8b treatment schemes of protocols A and B. B: RNA sequencing data for the expression of ventral midbrain (VM)-specific and hypothalamus-specific markers in organoid (Og)-NSCs calculated by two different FGF8b treatment schemes. C: Representative images of EN1+ / TH+mDA neurons induced by protocols A and B. Scale bar (50 μm)]. [Figure 8C] This shows that the maintenance of midbrain neural stem cells is efficiently improved by controlling the treatment time of FGF8, which is important for midbrain neurogenesis, by the method of the present invention [A: FGF8b treatment schemes of protocols A and B. B: RNA sequencing data for the expression of ventral midbrain (VM)-specific and hypothalamus-specific markers in organoid (Og)-NSCs calculated by two different FGF8b treatment schemes. C: Representative images of EN1+ / TH+mDA neurons induced by protocols A and B. Scale bar (50 μm)]. [Figure 9A]2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 9B] 2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 9C]2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 9D] 2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 9E]2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 9F] 2D-NSC generation from ventral midbrain (VM) neural stem / progenitor cells (NSCs) or hPSCs in a 2D culture environment: A: Requirement of astrocyte-conditioned medium (ACM) treatment during cell passaging of hPSCs differentiated in 2D. To prepare NSCs, hPSCs differentiated by VM patterning chemical treatment in the absence (-) or presence (+) of ACM (before top, upper panel) were isolated and plated (after passaging). Phase contrast and immunofluorescence staining images of cells expressing the indicated midbrain-specific factors are shown. B: Schematic of 2D culture-based hPSC-NSC / mDA neuron differentiation protocol. C: Immunofluorescence staining of VM-specific NSC marker expression in 2D-NSCs after 2 weeks of NSC expansion. D: Cell expansion of 2D-NSCs represented by population doubling level (PDL, bars) and cumulative PDL (lines). E–F: mDA neurons were generated from Og-NSCs after 12–15 days of differentiation. Midbrain-specific marker expression in DA neurons (% of TH+ cells) was quantified in three independent experiments (F). Scale bar, 50 μm]. [Figure 10]Representative images of neural stem / progenitor cells (NSCs) and mDA neurons expressing midbrain-associated markers in organoid-based cultures (top) and 2D-based cultures (bottom) are shown [Scale bar, 50 μm]. [Figure 11] The results illustrate that the developed protocol is a universally applicable protocol for human embryonic stem cells / induced pluripotent stem cells and various stem cell lines. [Ventral midbrain (VM) neural stem / progenitor cells (NSCs) and mDA neurons expressing midbrain-specific markers were generated in all hPSC lines tested. Three hESC lines and four hiPSC lines were induced to differentiate into VM-type NSCs using the organoid protocol outlined in Figure 1A. NSCs were expanded for 2–3 cell passages, and terminal differentiation of NSCs into mDA neurons was induced. Representative immunostaining images of FOXA2+, LMX1A+ NSCs at the NSC stage (expanded) and TH+ mDA neurons expressing midbrain markers FOXA2, LMX1A, NURR1, and EN1 after 7–12 days of terminal differentiation are depicted. Scale bar, 50 μm]. [Figure 12A]Results are illustrated showing that organoid (Og) neural stem / progenitor cells (NSCs) can be expanded into human mDA neurons and can be supplied sufficiently to be used as a universal cell therapy, in terms of quantity or maintenance of the biological properties of the cells. [A: Schematic of the organoid-based protocol using NSC expansion by 5 cell passages to generate 7,260 vials (9,075 dishes) of mDA neurons from one dish of undifferentiated hPSCs. B: Maintenance of mDA neurogenesis capacity of Og-NSCs over multiple NSC passages. The upper figure depicts representative immunostaining images of FOXA2+, LMX1A+ NSCs at the NSC stage (expansion), and TH+ mDA neurons expressing midbrain markers FOXA2, LMX1A, NURR1 and EN1 after 10-18 days of terminal differentiation. Midbrain marker expression in NSCs and mDA neurons was quantified in the lower graph. Independent experiments (n=3). C: Storage of Og-NSCs in liquid N2 does not alter mDA neurogenesis potential. Representative immunostaining images of mDA neurons differentiated from H9 Og-NSCs with (+) and without (-) liquid N2 storage are depicted. Scale bar, 50 μm. [Figure 12B]Results are illustrated showing that organoid (Og) neural stem / progenitor cells (NSCs) can be expanded into human mDA neurons and can be supplied sufficiently to be used as a universal cell therapy, in terms of quantity or maintenance of the biological properties of the cells. [A: Schematic of the organoid-based protocol using NSC expansion by 5 cell passages to generate 7,260 vials (9,075 dishes) of mDA neurons from one dish of undifferentiated hPSCs. B: Maintenance of mDA neurogenesis capacity of Og-NSCs over multiple NSC passages. The upper figure depicts representative immunostaining images of FOXA2+, LMX1A+ NSCs at the NSC stage (expansion), and TH+ mDA neurons expressing midbrain markers FOXA2, LMX1A, NURR1 and EN1 after 10-18 days of terminal differentiation. Midbrain marker expression in NSCs and mDA neurons was quantified in the lower graph. Independent experiments (n=3). C: Storage of Og-NSCs in liquid N2 does not alter mDA neurogenesis potential. Representative immunostaining images of mDA neurons differentiated from H9 Og-NSCs with (+) and without (-) liquid N2 storage are depicted. Scale bar, 50 μm. [Figure 12C]Results are illustrated showing that organoid (Og) neural stem / progenitor cells (NSCs) can be expanded into human mDA neurons and can be supplied sufficiently to be used as a universal cell therapy, in terms of quantity or maintenance of the biological properties of the cells. [A: Schematic of the organoid-based protocol using NSC expansion by 5 cell passages to generate 7,260 vials (9,075 dishes) of mDA neurons from one dish of undifferentiated hPSCs. B: Maintenance of mDA neurogenesis capacity of Og-NSCs over multiple NSC passages. The upper figure depicts representative immunostaining images of FOXA2+, LMX1A+ NSCs at the NSC stage (expansion), and TH+ mDA neurons expressing midbrain markers FOXA2, LMX1A, NURR1 and EN1 after 10-18 days of terminal differentiation. Midbrain marker expression in NSCs and mDA neurons was quantified in the lower graph. Independent experiments (n=3). C: Storage of Og-NSCs in liquid N2 does not alter mDA neurogenesis potential. Representative immunostaining images of mDA neurons differentiated from H9 Og-NSCs with (+) and without (-) liquid N2 storage are depicted. Scale bar, 50 μm. [Figure 13A]Screening of candidate compounds for PD drugs using mDA neurons induced from Pd-iPSCs [A: Schematic diagram of the experimental procedure. hiPSCs induced from a PD patient (PD-ips1) were differentiated into mDA neurons using an organoid-based protocol. Cell survival of PD-iPSC-mDA neurons was assessed in the presence of compounds using MTT analysis and immunofluorescence intensity-based counting of TH-positive DA neurons. High-content screening (HCS) analysis using Image Express Microconfocal (Molecular Devices, San Jose, CA) was used for TH intensity-based mDA neuron survival analysis. B: Example of screening data obtained by MTT analysis (top) and TH+ intensity measurement (bottom). The yellow line is the average value of the control group (vehicle). C: Representative TH / MAP2 images of PD-iPSC-derived mDA neurons at day 10 using vehicle (top) and compound #9]. [Figure 13B] Screening of candidate compounds for PD drugs using mDA neurons induced from Pd-iPSCs [A: Schematic diagram of the experimental procedure. hiPSCs induced from a PD patient (PD-ips1) were differentiated into mDA neurons using an organoid-based protocol. Cell survival of PD-iPSC-mDA neurons was assessed in the presence of compounds using MTT analysis and immunofluorescence intensity-based counting of TH-positive DA neurons. High-content screening (HCS) analysis using Image Express Microconfocal (Molecular Devices, San Jose, CA) was used for TH intensity-based mDA neuron survival analysis. B: Example of screening data obtained by MTT analysis (top) and TH+ intensity measurement (bottom). The yellow line is the average value of the control group (vehicle). C: Representative TH / MAP2 images of PD-iPSC-derived mDA neurons at day 10 using vehicle (top) and compound #9]. [Figure 13C]Screening of candidate compounds for PD drugs using mDA neurons induced from Pd-iPSCs [A: Schematic diagram of the experimental procedure. hiPSCs induced from a PD patient (PD-ips1) were differentiated into mDA neurons using an organoid-based protocol. Cell survival of PD-iPSC-mDA neurons was assessed in the presence of compounds using MTT analysis and immunofluorescence intensity-based counting of TH-positive DA neurons. High-content screening (HCS) analysis using Image Express Microconfocal (Molecular Devices, San Jose, CA) was used for TH intensity-based mDA neuron survival analysis. B: Example of screening data obtained by MTT analysis (top) and TH+ intensity measurement (bottom). The yellow line is the average value of the control group (vehicle). C: Representative TH / MAP2 images of PD-iPSC-derived mDA neurons at day 10 using vehicle (top) and compound #9]. [Figure 14] Figure 1 summarizes the development and cellular characteristics of mDA neurons in the developing midbrain (VM) by organoid (Og) neural stem / progenitor cell (NSC) differentiation in secondary culture. Terminal differentiation of Og-NSCs was induced by withdrawal of bFGF and the presence of neurotrophic factors BDNF, GDNF and cAMP. Immunocytochemistry analysis was performed at the indicated differentiation days using antibodies specific for proliferating cells (Ki67), mature neurons (MAP2), DA neurons (TH) and midbrain (FOXA2, LMX1A, NURR1). Scale bar, 50 μm. [Figure 15A] Single-cell RNA expression patterns of neural stem / progenitor cell (NSC)-specific genes (A), pluripotent cell-specific genes (B), and cellular senescence-specific genes (D) in organoids (Og) and 2D-NSCs (low expression levels of pluripotency genes SSEA4 and TRA1-60 were further assessed by FACS analysis (C)). [Figure 15B]Single-cell RNA expression patterns of neural stem / progenitor cell (NSC)-specific genes (A), pluripotent cell-specific genes (B), and cellular senescence-specific genes (D) in organoids (Og) and 2D-NSCs (low expression levels of pluripotency genes SSEA4 and TRA1-60 were further assessed by FACS analysis (C)). [Figure 15C] Single-cell RNA expression patterns of neural stem / progenitor cell (NSC)-specific genes (A), pluripotent cell-specific genes (B), and cellular senescence-specific genes (D) in organoids (Og) and 2D-NSCs (low expression levels of pluripotency genes SSEA4 and TRA1-60 were further assessed by FACS analysis (C)). [Figure 15D] Single-cell RNA expression patterns of neural stem / progenitor cell (NSC)-specific genes (A), pluripotent cell-specific genes (B), and cellular senescence-specific genes (D) in organoids (Og) and 2D-NSCs (low expression levels of pluripotency genes SSEA4 and TRA1-60 were further assessed by FACS analysis (C)). [Figure 16] We present a detailed protocol for isolating cortical neural stem cells using 3D cortical organoids. [Figure 17] Showing that neural stem cells can be obtained using 3D cerebral cortical organoids [Left graph: The suitability of the differentiation protocol was confirmed by the expression of pax6, a cerebral marker. Right: In the upper photo, the formation of organoids with the correct morphology was confirmed by photography before chopping the organoids. In the lower photo, the proliferation of normal neural stem cells was confirmed after chopping]. [Figure 18] The final established directed differentiation protocol from 2D and 3D derived cultures to mesencephalic neural stem cells is shown. [A: Establishment of a stepwise technique for directed differentiation from embryonic stem cells to mesencephalic neural stem cells using human embryonic stem cells, obtaining astrocyte precursor cells, and then final differentiation to astrocytes. B: Protocol for obtaining cerebral cortex-derived astrocytes. (A) has a different patterning method from (B)]. [Figure 19]We show the preparation of astrocytes using a directed differentiation protocol from 2D and 3D derived media to mesencephalic neural stem cells. The cells derived by the method of the present invention are shown to be healthier and have improved marker maintenance compared to traditional two-dimensional culture methods. [Figure 20] We present the results of analyzing the characteristics of in vitro cultured cerebral cortex- and midbrain-type astrocytes, demonstrating that midbrain-derived astrocytes are superior in genetic analysis of the actual supportive function of neurons in the two astrocytes. [Figure 21] The results of analyzing the properties of cerebral cortex- and midbrain-type astrocytes after in vivo transplantation are shown below. Midbrain-derived astrocytes are superior in genetic analysis of the actual supportive function of neurons in the two astrocytes. [Figure 22] This shows that the transplantation of astrocyte precursor cells in vivo changes microglia into high-quality M2 type cells. It is expected that this will be of great use in the case of transplanting astrocytes in the future, as it can improve the environment. [Diagram 23] The results of other types of adaptation culture of induced pluripotent stem cells using xeno-free system are shown. This is a fundamental result because it is important to apply xeno-free system to various cell lines when developing cell therapy drugs in practice. [Figure 24] Confirmation of protocol application from another type of induced pluripotent stem cells (CMC-iPSC#11) to midbrain-type astrocytes (left side), and confirmation of normal neuronal differentiation (right side) are shown. [Diagram 25] The application of the protocol to another type of induced pluripotent stem cell (CMC-iPSC#11) was confirmed, and the results obtained are shown. [Figure 26] The results obtained by confirming the application of the protocol via efficient differentiation induction using TGF-β and LIF are shown. [Figure 27] The results obtained by analyzing the physiological properties of the generated midbrain astrocytes are shown. [Figure 28]We present results obtained by observing changes in microglia using medium conditioned for midbrain-type astrocytes, thereby validating the anti-inflammatory effect of astrocytes in vitro. [Figure 29] We present results obtained by inducing inflammation and then confirming the possibility of astrocyte-conditioned medium to inhibit death factors, thereby validating the anti-inflammatory effect of astrocytes in vitro. [Diagram 30] The results are shown by inducing inflammation and then confirming the anti-inflammatory effect of astrocyte-conditioned medium using RT-PCR, thereby validating the anti-inflammatory effect of astrocytes in vitro. [Diagram 31] We present results obtained by analyzing the expression of RNA related to non-coding regions and inflammatory responses after transplantation of astrocytes into the striatum, thereby validating the anti-inflammatory effect of astrocytes in vivo. [Diagram 32] Figure 2 shows the expression of iNOS, an M1 marker, after astrocyte transplantation in vivo. Less inflammation was observed in the area compared to the area of ​​neural stem cell transplantation. [Diagram 33] Figure 2 shows the expression of the M1 marker CD11b after astrocyte transplantation in vivo. Less inflammation was observed in the area compared to the area of ​​neural stem cell transplantation. [Diagram 34] Figure 2 shows the expression of the M1 marker CD16.32 after astrocyte transplantation in vivo. Less inflammation was observed in the area compared to the area of ​​neural stem cell transplantation. [Diagram 35] Figure 2 shows the expression of the M2 marker CD206 after astrocyte transplantation in vivo. Less inflammation was observed in the area compared to the area of ​​neural stem cell transplantation. [Diagram 36] We present a detailed protocol for isolating hypothalamic neural stem cells using 3D organoids. [Figure 37]The results obtained by obtaining 3D hypothalamic organoids and confirming the expression of appropriate markers are shown, with specific markers such as nestin, Rax, and Sox2 being sufficiently expressed. [Figure 38] The results obtained by confirming that hypothalamic neural stem cells capable of proliferation were obtained are shown below. [A: Securing neural stem cells capable of proliferation up to 4 passages that express 97% of the hypothalamic neural stem cell marker Nestin / Rax. B: Confirming the expression of hypothalamus-related genes in hypothalamic neural stem cells] [Figure 39] The results obtained by inducing differentiation of hypothalamic neural stem cells and then confirming normal neuronal and astrocyte differentiation are shown. [Diagram 40] The results obtained by inducing differentiation of hypothalamic neural stem cells and then confirming their differentiation into cells responsive to leptin are shown. This functional analysis fully demonstrated the functional characteristics of hypothalamic cells, and the expression of NPY and AGRP, which are markers of hypothalamic neurons, increased after differentiation. Thus, it was confirmed that the patterning into the desired hypothalamic neural stem cells was fully performed both functionally and in terms of marker expression. [Diagram 41] We show that hypothalamic neural stem cells generated using 3D organoids express a greater set of marker genes in vivo than those generated in a two-dimensional (2D) environment. [Diagram 42] We present results obtained by validating the feasibility of in vivo transplantation of hypothalamic neural stem cells generated using 3D organoids.

[0015] [Best Mode for Carrying Out the Invention] The invention is described in more detail herein below.

[0016] The present invention relates to methods for patterning and chopping 3D organoids prepared from human pluripotent stem cells, culturing stem or progenitor cells, and inducing differentiation of stem or progenitor cells to obtain large quantities of terminally differentiated cells.

[0017] As used herein, the term "pluripotent stem cells (PSCs)" refers to stem cells that can be induced to differentiate into any type of cell that makes up the body, and pluripotent stem cells include embryonic stem cells (ESCs) and induced pluripotent stem cells (Ipsc, dedifferentiated stem cells).

[0018] As used herein, the term "organoid" refers to a "mini-organ mock-up" created using stem cells to have minimal function, characterized by being created in a three-dimensional structure and being able to create an environment similar to an actual body organ even in a laboratory. That is, "organoid" refers to cells having a 3D structure, and refers to a model similar to an organ, such as nerves and intestines, prepared by an artificial culture method that is not collected or obtained from an animal or the like. The origin of the constituting cells is not limited. Organoids may have an environment that allows them to interact with the surrounding environment in the process of cell growth. Unlike 2D culture, 3D cell culture allows cells to grow in all directions ex vivo. Therefore, in the present invention, 3D organoids can be an excellent model for observing the development of therapeutic agents for diseases, etc., by almost completely mimicking the organs that actually interact in vivo.

[0019] Organoid can generally be prepared by culturing human pluripotent stem cells.Specifically, organoid can be differentiated from Parkinson's disease-induced induced pluripotent stem cells into neuroectodermal sphere, or can be differentiated from Parkinson's disease-induced induced pluripotent stem cells into definitive endoderm and hindgut through stepwise differentiation into intestinal organoid.

[0020] As used herein, the term "differentiation" refers to the phenomenon in which the structure or function of a cell is specified during the differentiation and proliferation of the cell and the growth into a whole individual. In other words, it refers to the process of changing the cells, tissues, etc. of an organ into the appropriate morphology and function to perform the corresponding predetermined role. For example, differentiation may include the process in which pluripotent stem cells are transformed into ectoderm (cerebral cortex, midbrain, hypothalamus, etc.), mesoderm (yolk sac, etc.) and endoderm cells, and the process in which hematopoietic progenitor stem cells are transformed into red blood cells, white blood cells, platelets, etc., i.e., the process in which progenitor cells express specialized differentiation traits.

[0021] Existing methods for directly inducing differentiation from human pluripotent stem cells into corresponding cells have problems with reproducibility depending on the cell line or laboratory (experimental environment), and cannot achieve stable expression of maintenance factors. For example, in the case of midbrain dopamine neurons, unlike the actual in vivo environment, astrocytes do not exist together, and there is a limit to the number of final cells that can be obtained in one differentiation. In one embodiment of the present invention, compared with the two-dimensional differentiation-derived cell population, patterning and preparing organoids that can sufficiently contain cerebral astrocyte precursor cells, midbrain astrocyte precursor cells, midbrain dopaminergic neural stem cells, or hypothalamic neural stem cells (enriched target cells), i.e., ensuring organoids containing the maximum amount of each target cell, and chopping the organoid tissue and culturing the corresponding stem cells or progenitors, it is possible to obtain differentiation into cell populations that can make stem cells or progenitors more similar to cells isolated from the actual brain, can sufficiently maintain their characteristics, and can obtain viability.

[0022] As used herein, the term "patterning" refers to the preparation of organoids, such that the method comprises the cell populations of fate that have the characteristics of the origin tissue cells that are finally extracted from detailed brain tissue by, for example, midbrain type patterning, cerebral cortex type patterning or hypothalamic type patterning as a plurality of cell populations (enriched target cells).In addition, patterning markers include Lmx1a, Foxa2, Nurr1 and En1 for midbrain type patterning, Pax6 and Foxg1 for cerebral cortex type patterning, Rax and Nkx2.2 for hypothalamic type patterning, etc.

[0023] Therefore, in the present invention, terminally differentiated cells can be obtained in large quantities at once by chopping the prepared 3D organoids, isolating stem cells that can be expanded from the organoids, and culturing and expanding the stem cells.

[0024] According to one embodiment of the present invention, the present invention provides a method for chopping 3D organoids prepared from human pluripotent stem cells to obtain large amounts of stem or progenitor cells for terminal differentiation, comprising: 1) Proliferate and culture human pluripotent stem cells to prepare 3D organoids; 2) patterning and chopping the prepared 3D organoids; and 3) culturing and expanding stem or progenitor cells in the cells extracted from the chopped organoids and inducing their differentiation to obtain large amounts of terminally differentiated cells; The method includes the steps of:

[0025] The stem cells may be ectodermal stem cells (skin and nerve cells), mesodermal stem cells (muscle and bone cells), or endodermal stem cells (digestive and respiratory cells). In particular, they may be midbrain dopaminergic neural stem cells or hypothalamic neural stem cells.

[0026] The progenitor cells may be, but are not limited to, cerebral astrocyte progenitor cells or mesencephalic astrocyte progenitor cells.

[0027] The cells can be, but are not limited to, neurons or astrocytes.

[0028] More preferably, human pluripotent stem cells and stem cells are cultured using vitronectin. In this regard, vitronectin is preferably used at a concentration of 0.3 to 0.7 μg / cm 2 To date, CellStemCell of Parmar group (A. Kirkeby et al., Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease. Cell Stem Cell 20, 135-148 (2017).) and Nature Protocol (S. Nolbrant, A. Heuer, M. Parmar, A. Kirkeby, Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nature protocols 12, 1962-1979 (2017)) have reported the latest research on mass production of dopaminergic neurons for transplantation, and have used Lamin 521 (BioLamina LN-521) at 0.5 μg / cm for the proliferation and culture of human embryonic stem cells. 2 and lamin 511 (Biolamin LN-511) at 1 μg / cm after differentiation into midbrain neurons. 2 In contrast, it was reported that the use of vitronectin (Gibco A31804) at 0.5 μg / cm 2was used for both human embryonic stem cell culture and mesencephalic neural stem cell culture. With regard to the unit cost of coating a 60 mm dish commonly used for culture, the price of Lamin 521 for culturing human embryonic stem cells is 7,282 won / dish, the price of the vitronectin of the present invention is 1,480 won / dish, and the price of Lamin 511 for culturing mesencephalic neural stem cells is 23,832 won / dish, while the price of the vitronectin used continuously in the present invention is 1,480 won / dish. If only the coating cost is considered, the method of the present invention has a 5-fold saving effect when culturing human embryonic stem cells and a 16-fold saving effect when culturing mesencephalic neural stem cells.

[0029] As used herein, the term "large quantity" means that, although there are differences depending on each patterned cell population, when one culture dish of pluripotent stem cells is introduced at the beginning to be used, it is possible to obtain about 1,000 to 7,200 vials of frozen cells, and when one or two culture dishes of cells are generally frozen in one vial, it refers to an amount that increases by about 1,000 to 14,000 times. In particular, it includes not only simple quantitative proliferation but also maintenance of characteristics.

[0030] As used herein, the term "glia" refers to the cells that represent the largest proportion of cells present in the brain, and refers to "astrocytes." Astrocytes, also called microglia, are involved in protecting neurons and providing nutrients and inflammation, and microglia are the cells responsible for inflammation in the brain.

[0031] Astrocytes can be obtained by differentiation from embryonic or adult stem cells, or by isolation from the midbrain (ventral midbrain), cerebral cortex (cortex) or lateral ganglionic eminence (striatal anlage) in mammals.

[0032] "Neural stem / progenitor cells (NSC / NPCs)" can be isolated and cultured from brain tissue, either from developmental or adult brain tissue, and the cultured NPCs can be used for the mass generation of dopamine neurons for research and drug screening.

[0033] A "neuronal cell" is a cell of the nervous system, and the terms "neuron" or "neuronal cell" may be used interchangeably.

[0034] "Dopamine (DA) neurons" refer to neurons that express tyrosine hydroxylase (TH). In the present invention, "dopaminergic neurons", "dopamine neurons", "DA" and the like are used interchangeably. Dopamine neurons are specifically located in the substantia nigra of the midbrain and innervate the striatum, limbic system and neocortex in vivo to control postural reflexes, locomotion and reward-related behaviors.

[0035] The present invention also includes a cell therapeutic agent comprising the cells obtained by the above method.

[0036] "Cell therapy" refers to drugs used for treatment, diagnosis and prevention by cells and tissues prepared from a subject through isolation, culture and special modification (US FDA regulations). It refers to drugs used for treatment, diagnosis and prevention purposes through a series of actions, such as ex vivo expansion or selection of living autologous, allogeneic or xenogeneic cells, or alteration of the biological properties of cells through other methods to restore the function of cells or tissues. Cell therapy is broadly classified into somatic cell therapy and stem cell therapy according to the degree of cell differentiation.

[0037] As used herein, the term "subject" refers to a vertebrate, preferably a mammal, such as cows, pigs, cows, goats, dogs, cats, rats, mice, rabbits, guinea pigs, humans, etc., that is treated, observed or experimented upon.

[0038] As used herein, the term "treatment" refers to any action that inhibits, alleviates, or favorably alters the clinical condition associated with a disease. In addition, treatment can mean increased survival compared to expected survival in the absence of treatment. Treatment includes prophylactic as well as therapeutic methods.

[0039] The cell therapeutic agent of the present invention exhibits a therapeutic effect on a disease selected from the group consisting of neurodegenerative diseases, inflammatory degenerative diseases, and metabolic diseases.

[0040] Neurodegenerative diseases may include, for example, but are not limited to, those selected from the group consisting of Parkinson's disease, dementia, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, memory loss, myasthenia gravis, progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, diffuse Lewy body disease, and Pick's disease.

[0041] The inflammatory degenerative disease may include, but is not limited to, those selected from the group consisting of dementia, dementia with Lewy bodies, frontotemporal dementia, white matter degeneration, adrenoleukodystrophy, multiple sclerosis, and Lou Gehrig's disease.

[0042] The metabolic disease may include, but is not limited to, those selected from the group consisting of diabetes, obesity, and metabolic disorders.

[0043] The cells obtained by the method of the present invention can be applied as a cell therapy agent, and can be formulated by further including a pharma- ceutically acceptable carrier. As used herein, the term "pharma- ceutically acceptable carrier" refers to a carrier or diluent that does not significantly stimulate an organism and does not inhibit the biological activity and properties of an administered compound. In the present invention, the pharma- ceutically acceptable carrier that can be included in the cell therapy agent can be used without limitation as long as it is known in the art, for example, a buffer, a preservative, an analgesic, a solubilizer, an isotonic agent, a stabilizer, a base, an excipient, a lubricant, etc. The cell therapy agent of the present invention can be prepared into various formulations by commonly used techniques. The cell therapy agent of the present invention can be administered by any route as long as it can induce migration to the disease site. In some cases, a method of loading stem cells into a vehicle equipped with a means for directing them to the lesion can also be considered. Thus, the cell therapy agent of the present invention can be administered via several routes, including topical (including oral, sublingual, dermal and intraocular administration), parenteral (including subcutaneous, intradermal, intramuscular, instillation, intravenous, intraarterial, intraarticular and intracerebrospinal fluid), or transdermal administration, and is preferably administered directly to the disease site. In one embodiment, the cells may be administered to an individual by suspending the agent in a suitable diluent, which is used to protect and maintain the cells when injected into the target tissue, as well as to facilitate use. Diluents may include saline, phosphate buffer solution, buffer solutions such as HBSS, cerebrospinal fluid, and the like. In addition, the pharmaceutical composition may be administered by any device that allows the active substance to move to the target cells. The preferred mode of administration and preparation is injection. The injection may be prepared using an aqueous solution, such as saline, Ringer's solution, Hank's solution or sterile aqueous solution, vegetable oils such as olive oil, higher fatty acid esters such as ethyl oleate, non-aqueous solutions such as ethanol, benzyl alcohol, propylene glycol, polyethylene glycol or glycerin, and the like.For mucosal penetration, non-permeable agents known in the art suitable for passing through barriers may be used, and may further include pharmaceutical carriers, such as stabilizers to prevent deterioration, such as ascorbic acid, sodium bisulfite, BHA, trophodol, EDTA, etc., and emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth, such as phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, and benzyl alcohol.

[0044] The present invention also provides a drug screening method using the cells or progenitor cells obtained by the above method.

[0045] Important features of the cells obtained by the present invention include the possibility of ensuring the generation of large numbers of cells, maintaining the characteristics even during cryopreservation, the possibility of maintaining the same cell population for a long period of time, and differentiation more similar to cells derived from living organisms. This characteristic is particularly suitable for screening a large number of drugs simultaneously, which requires a large number of cells in the same state, and the key is to ensure the same cells for repeated analysis over a long period of time. This is very suitable for screening cells, since the cell population with the same characteristics, in which key markers are maintained, can be used continuously from the beginning to the end of the screening procedure.

[0046] The drug is a drug for treating a disease selected from the group consisting of neurodegenerative diseases, inflammatory degenerative diseases, and metabolic diseases, and exhibits a therapeutic effect on a disease selected from the group consisting of neurodegenerative diseases, inflammatory degenerative diseases, and metabolic diseases.

[0047] Neurodegenerative diseases can include various nervous system diseases, including, but not limited to, Parkinson's disease, dementia, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, memory loss, myasthenia gravis, progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, diffuse Lewy body disease, and Pick's disease.

[0048] Inflammatory degenerative diseases may include, but are not limited to, those selected from the group consisting of dementia, dementia with Lewy bodies, frontotemporal dementia, white matter degeneration, adrenoleukodystrophy, multiple sclerosis, and Lou Gehrig's disease.

[0049] The metabolic disease may include, but is not limited to, those selected from the group consisting of diabetes, obesity, and metabolic disorders.

[0050] All technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs, unless otherwise defined. In addition, although preferred methods and examples are described herein, similar or equivalent are also included within the scope of the present invention. The contents of all publications referenced herein are incorporated herein by reference.

[0051] [Mode for carrying out the invention] Hereinafter, the present application will be described in detail through examples. The following examples are for illustrating the present application, and the scope of the present application is not limited by the following examples.

[0052] [Example] Example 1: Differentiation of human induced pluripotent stem cells into mDA (midbrain dopamine) neurons using midbrain organoids [Experimental Method] Cultivation of human embryonic stem cells or human induced pluripotent stem cells hESCs and hiPSCs were cultured in accordance with the hESC research guidelines approved by the Institutional Review Board (IRB) of Hanyang University (Seoul, Republic of Korea). The hESCs and hiPSCs used in this experiment are shown in Table 1 below.

[0053] [Table 1]

[0054] For the proliferation and maintenance of undifferentiated hESCs / iPSCs, cells were cultured in a CO2 incubator set at 37°C without a feeder layer using mTESR-1 medium (Stemcell Technologies Inc., Vancouver, BC, Canada) with Matrigel™ or Vitronectin (Human, Gibco Fisher Scientific, Waltham, MA) (Gibco A31804, 0.5 μg / cm 2 The undifferentiated stem cells were cultured on 100% PBS-coated 6 cm dishes (Thermo Fisher Scientific, Waltham, MA) with daily medium changes. The differentiation potential of the undifferentiated stem cells was maintained by daily medium changes and subcultured using Acutase (Stemcell Technologies Inc.) every 4–5 days.

[0055] Preparation of mesencephalic neural stem cells using a 3D organoid preparation method Briefly, we used a system in which midbrain-type 3D organoids were first prepared, cut into small pieces, and then massively expanded in culture dishes in the state of midbrain-type neural stem cells.

[0056] hESCs and hiPSCs, which are usually cultured in an undifferentiated state, were separated by using Accutase (trademark) during secondary culture, and the undifferentiated human embryonic stem cells were aliquoted into a 96-well plate with a round bottom, and organoids were formed at 10,000 cells / well at a time without sticking to the bottom. For the medium composition on the first day, organoid generation was started with the addition conditions corresponding to day 0 in Table 2 in the seeding basal medium in Table 4 below (SB431542, 10 μM; Noggin, 100 ng / ml; ascorbic acid, 200 μM; doxycycline, 1 μg / ml; Y27632, 20 μM). The next day, neural induction basal medium (Table 3) was used as the medium, and development was induced by additionally adding purmorphamine 2 μM and sonic hedgehog 100 ng / ml to the components, except for doxycycline 1 μg / ml and Y27632 20 μM (see Table 2) among the components added on the first day. The culture medium was neural induction basal medium until day 11, and development was induced by adding or subtracting additives according to the concentrations referred to in Table 2 for the added components. The medium was changed every day according to the date. The correct formation of organoids was confirmed by the formation of cell clusters on day 2 or 3, and was examined by the outward budding of cells before day 11. On the 11th day of organoid differentiation, eight organoids formed in the 96-well plate were divided into each group one by one, aliquoted into the corresponding 6-well low-binding plate, and cultured there. Development was induced in midbrain patterning basal medium (Table 3) containing the components in Table 2 while rotating on an orbital shaker (80-100 rpm). On day 18, one organoid was cut into approximately 4-10 pieces with a 30G needle, treated with Accutase™ for 10 min, then pipetted 5 times with a 1 ml pipette, Accutase™ was then removed by centrifugation, and 3 wells of organoids were then plated with Poly-L-ornithine (PLO, 15 μg / cm 2 ) / fibronectin (FN, 1 μg / cm 2 ) or vitronectin (VN, 0.5 μg / cm 2 The cells were plated in the center of one 60 mm culture dish coated with 100% ethanol.

[0057] [Table 2-1] [Table 2-2]

[0058] [Table 3]

[0059] Massive expansion of midbrain-type neural stem cells derived from midbrain 3D organoids Organoid-derived midbrain neural stem cells were physically cut with a 30G needle. After initial plating for secondary culture, when the cells were approximately 80-90% full, 3 × 10 6 The cells were cultured once a week for secondary culture on 60 mm culture dishes coated with PLO / FN or PLO / VN using Accutase™. For the culture medium of mesencephalic neural stem cells, the medium supplemented with mitogens (bFGF 20 ng / ml, FGF-8 50 ng / ml), BDNF (20 ng / ml), GDNF (20 ng / ml), ascorbic acid 200 μM, and doxycycline 1 μg / ml was used as the growth medium. However, on the day of secondary culture, Y27632 20 μM was added to this medium. 8 × 10 cells per well were cultured for each secondary culture. 4 Cells were plated on PLOVN 24-well coated plates and grown for 2-3 days. When 80-90% cell confluency was achieved, differentiation of NSCs was induced by fluorescent staining of midbrain-type markers or by withdrawal of mitogens (bFGF, FGF-8). In the differentiation medium, BDNF (20 ng / ml), GDNF (20 ng / ml), ascorbic acid 200 μM and cAMP 500 μM were added to the midbrain patterning basal medium shown in Table 4 above to induce neuronal differentiation for 12 days, and then co-expression of dopaminergic neurons and midbrain-type markers was examined.

[0060] Cryopreservation of 3D organoid-derived midbrain neural stem cells Organoid-derived midbrain neural stem cells generally do not change characteristics until at least 5 passages, so the cells can be thawed and used without changing characteristics after cryopreservation of the cells for all passages after the first passage. Cryopreservation of the cells is performed during subculture, where the cells are detached using Accutase™, the number of cells is counted, and 6×10 6 The cells were thawed and frozen in one cryovial with growth medium and freezing medium mixed with DMSO at a concentration of 10%. The cells were stored frozen at -70°C for the first 24 hours, and then the next day in a cryogenic nitrogen tank until use. If necessary, one vial was quickly thawed in a 37°C water bath and the cells were plated on a 60 mm culture dish coated with PLO / FN or PLO / VN. For thawing, neural stem cell growth medium was used, and on the day of thawing, 20 μM Y27632 was added to the medium.

[0061] immunocytochemistry Cells were fixed with 4% paraformaldehyde in PBS (phosphate buffered saline), incubated in blocking solution (1% BSA / 0.03% Triton X-100 in PBS) and then incubated with the following primary antibodies: Tuj1 anti-rabbit (1:2000, Babco), TH anti-mouse (1:1000, Immunostar), GFAP anti-mouse (1:100, ICN Biochemicals), microtubule associated protein 2 (MAP2, 1:200, Sigma). Secondary antibodies labeled with the following fluorescent molecules were used for visualization. Other antibodies are listed in Table 4: Alexa 488 (1:200, Invitrogen) and Cy3 (1:200, Jackson ImmunoResearch Laboratories). Stained samples were mounted in Vectashield (Vector Laboratories) with DAPI mounting medium and photographed using an epifluorescence microscope (Leica).

[0062] [Table 4-1] [Table 4-2]

[0063] Cell transplantation and histological procedures in Parkinson's disease animal models Experiments were performed according to NIH guidelines. Hemiparkinsonism was induced in adult female Sprague-Dawley rats (220-250 g) by stereotaxic injection of 3 μl of 6-OHDA (6-hydroxydopamine, 8 μg / μl, Sigma) alone into the right substantia nigra (AP-4.8 mm, ML-1.8 mm, V-8.2 mm) and MFB (medial forebrain bundle) (AP-4.4 mm, ML-1.2 mm, V-7.8 mm). The incisor bar was set at -3.5 mm, and AP and ML coordinates were presented relative to the anterior crest of the bregma. Rats with 300 rotations / h on the same side due to the lesion were selected for amphetamine-induced rotation testing. For transplantation, rat E12 VM-NPCs were expanded and mixed with Ctx-VM astrocytes, N+F-VM-astrocytes, or E14 Ctx-NPCs (control group) at a ratio of 2:1. 3 μL of mixed cells (1.5 × 10 5100 cells / μL) were injected into each of two sites in the striatum (AP, ML and V coordinates relative to the bregma and dura: [1] 0.07, -0.30, -0.55; [2] -0.10, -0.40, -0.50; incisor bar set 3.5 mm below zero) over a 10-minute period under anesthesia induced with 100 μl / 100 g (50 mg / ml) Zoletil mixed with 100 μl / 100 g (23.32 mg / ml) Rompun. The needle (22 gauge) was left in place for 5 minutes after each injection was completed. Rats were administered cyclosporine A (10 mg / kg, ip) daily for 1 month starting 1 day before transplantation and were maintained without immunosuppressant drugs for the remainder of the post-transplant period. Six months after transplantation, animals were anesthetized and perfused percutaneously with 4% paraformaldehyde. Brains were removed, immersed overnight in 30% sucrose in PBS, frozen in Tissue-Tek® (Sakura Fineteck, Torrance, CA, USA), and then sectioned with a freezing microtome (Leica). Free-floating brain sections (30 μm thick) were subjected to immunohistochemistry as described above and imaged with a confocal microscope (Leica). For experiments testing the host environment of the transplanted brain, animals were sacrificed 1 month after transplantation and sectioned at 1 mm thickness with a rat brain slice matrix (ZIVIC Instruments, Pittsburgh, PA). To observe changes after transplantation, tissues from the transplantation site were extracted. The graft-host interface (approximately 2 × 2 mm) / 8-12 regions of the graft were cut out and qPCR analysis was performed. In addition, cellular immune responses to neurotrophic and proinflammatory glial markers were counted along with the graft-host interface in frozen-sectioned brain sections 7–10 days after transplantation.

[0064] Behavioral testing Animal behavior was evaluated using the apomorphine / amphetamine-induced rotation test as described in the article by YH Rhee et al. (LIN28A enhances the therapeutic potential of cultured neural stem cells in a Parkinson's disease model. Brain: a journal of neurology 139, 2722-2739 (2016)). Apomorphine (Sigma) was injected subcutaneously at a dose of 0.5 mg / kg and the animals were observed for 60 min with rotation. Results are expressed in units of final number of rotations / 60 min.

[0065] Animal PET / MRI Imaging and Analysis PET / MRI fusion imaging was performed using a nanoScan PET / MRI system (1T, Mediso, Hungary). 0.2 mL of FP-CIT was administered intravenously into the tail vein at 6.5 ± 1.0 MBq to keep the mice warm, and the rats were kept under anesthesia (1.5% isoflurane in 100% O2 gas). MR brain imaging was performed using a gradient echo (GRE) 3D sequence (TR = 25 ms, TE eff Weighted T1 images were obtained with a fast spin echo (FSE) 3D sequence (TR = 2400 ms, TE effT2 images weighted with (T = 110, FOV = 50 mm, matrix = 256 × 256) were acquired during the FP-CIT acquisition time. Twenty minutes of static PET images were acquired at 1-3 coordinates in a single field of view within the MRI volume. Body temperature was maintained with hot air to the animal bed (Multicell Mediso, Hungary) and respiration was induced using a pressure-sensitive pad. PET images were reconstructed by Tera-Tomo 3D in detector full mode with 8 iterations, with all corrections and high normalization. Three-dimensional VOI (volume of interest) analysis of the reconstructed images was performed using the InterView Fusion software package (Mediso, Hungary) applying standard uptake value (SUV) analysis. VOIs were fixed to 2 mm spheres in the coronal images and a VOI of the striatum was derived. The SUV of each VOI site was calculated using the following equation: SUV mean = (tumor radioactivity in tumor volume of interest in Bq / cc × body weight) / radioactivity injected

[0066] High-throughput whole-transcriptome RNA sequencing For RNA, total RNA was isolated using Trizol reagent (Invitrogen), and then rRNA removal was performed using the Ribo-Zero Magnetic kit (Epicentre Inc., Madison, WI, USA). Library construction was performed using the SENSE mRNA-Seq Library Prep Kit (Lexogen Inc., Vienna, Autria). High-throughput sequencing was performed as paired-end 100 sequencing using a HiSeq 2000 (Illumina, San Diego, CA, USA). RNA-Seq read values ​​were mapped using TopHat software to obtain bam alignment files. Read counts mapped to transcribed regions were extracted from alignment files using BEDTools (v2.25.0) and R / Bioconductor (version 3.2.2; R Development Core Team, 2011). Alignment files were used to assemble transcriptomes, estimate abundance, and detect differential expression of genes, linc RNAs, or isoforms. FPKM (fragments per kb of exon per million fragments) was used to determine expression levels of genic regions. Global normalization was used for comparison between samples. Gene classification was based on work submitted by DAVID (http: / / david.abcc.ncifcrf.gov / ).

[0067] GO and KEGG pathway analyses were performed using DAVID Bioinformatics Resources version 6.8. GO and KEGG pathway analyses of rich categorizations presented p-values ​​up to 0.05.

[0068] 10x Genomics Single-Cell RNA Sequencing (scRNA-seq) and Data Analysis Single cell transcription factor regulation analysis (scRNA-seq) was performed using the Chromium Controller (10x Genomics, San Francisco, CA) program after experiments with Chromium Single cell Gene Expression Solution and Chromium Single Cell 3'GEM, Library and Gel Bead Kit v2 (10x Genomics). 15,000 dissociated single cells were placed on a Single cell A chip with Master mix solution. In each single cell, intracellular transcription factors were reverse transcribed and RNA barcoded by emulsion of oligo-dT-encoded UMIs. Barcoded libraries were sequenced on an Illumina Hiseq 4000 platform (Macrogen Inc., Seoul, Korea). Results were analyzed with Cell Ranger (v2.1.1, 10x Genomics). For 2D-NSC analysis, 12,166 cells were analyzed with a 2D_cell ranger average of 57,343 reads per cell and 2,284 genes (out of a total of 24,055 genes), and for Og-NSC analysis (3D_cell ranger), 13,739 cells were analyzed with an average of 39,191 reads per cell and 2,353 genes (out of a total of 23,860 genes). Cellular transcription factor expression was expressed as UMI counts. Cellular diversity analysis was performed by k-means clustering for t-SNE (t-distributed stochastic neighbor embedding) analysis (performed by Loupe Cell Browser version 3.0.1, 10x Genomics, Inc.). The top 40 genes with increased expression showing significant differences in expression were analyzed with a hierarchical clustering analysis method, and each cluster was separated based on this. In the GO and KEGG pathway analysis of Og-NSCs, 580 differentially up-regulated genes (UMI>1, log2FC>0.5, P<0.05) were analyzed.Genetic analysis was primarily performed using DAVID (http: / / david.abcc.ncifcrf.gov / ). Network analysis was performed using Cytoscape (version 3.7.1+JAVA v8, provided by NIGMS).

[0069] Analysis of mitochondrial function Mitochondrial regeneration dynamics were analyzed using integrated portions of young (green) and old (red) mitochondrial proteins (Ferree, A.W., Trudeau, K., Zik, E., Benador, I.Y., Twig, G., Gottlieb, R.A., and Shirihai, O.S. (2013). MitoTimer probe reveals the impact of autophagy, fusion, and motility on subcellular distribution of young and old mitochondrial protein and on relative mitochondrial protein age. Autophagy 9, 1887-1896; Hernandez, G., Thornton, C., Stotland, A., Lui, D., Sin, J., Ramil, J., Magee, N., Andres, A., Quarato, G., Carreira, R.S., et al. (2013). MitoTimer: a novel tool for monitoring mitochondrial turnover. Autophagy 9, 1852-1861). pMitotimer vector (Addgene 52659, Addgene, Watertown, MA) was injected into NSC cells by electroporation (NEPA21, Nepagene, Japan) to allow expression, and then mitochondria produced were examined by red vs. green fluorescence 2 days later. Mitochondrial ROS and membrane potential were measured by Mitosox (Thermo Scientific Inc., Waltham, MA) and NucleoCounter 3000 (NC3000, Chemometec, Allerod, Denmark), respectively. ROS production was analyzed for induction after treatment with H2O2 (500 μM) for 2 h before analysis. To study mitochondrial toxicity resistance, mitochondria were treated with 10 μM rotenone, 4 μM CCCP or 250 μM H2O2 for 1 h and analyzed by TH fluorescence staining.

[0070] Analysis of DA release Presynaptic activity of DA neurons was determined by measuring the levels of DA neurotransmitter released from differentiated VM-NPC cultures. The medium of 24 h culture (days 12–13 of differentiation) was collected and DA levels were measured using an ELISA kit (BA E-5300, LDN). In addition, DA release induced by membrane depolarization was assessed by culturing in fresh N2 culture medium for 30 min in the presence or absence of 56 mM KCl (day 12 cultures). Induced DA release was calculated by subtracting DA release without KCl from DA levels with KCl.

[0071] Analysis of intercellular α-synuclein transmission Confirmation of intercellular transfer of α-synuclein aggregates mediated by factors secreted from astrocytes Analytical experiments were performed using co-cultures of A53T α-synuclein EGFP-overexpressing SH-SY5Y (Professor Sang Myun Park, Ajou University) cells derived from neuroblastoma.

[0072] SH-SY5Y cells induced to differentiate using RA for 5 days and to express A53T α-synuclein EGFP were co-cultured for 24 hours with neural stem cells induced to differentiate for 10 days in a dual chamber system, and the transfer of A53T α-synuclein EGFP was compared to the level of GFP expression. α-synuclein transfer was confirmed by immunostaining (immunocytochemistry) via the brightness of α-synuclein GFP using antibodies.

[0073] Detection of pathological α-synuclein aggregation Upon differentiation, the medium (8 μg / ml of medium) was treated with α-synuclein aggregates, PFF (preformed fibrils), to induce α-synuclein aggregation, and the level of α-synuclein aggregation was analyzed 20 days after differentiation. Alternatively, overexpression was induced using lentivirus-expressed α-synuclein (pEF1α-α-synuclein) and analyzed. Immunostaining (immunocytochemistry) using Thioflavin S (a staining method that measures protein aggregation, Sigma Aldrich), as well as α-synuclein antibodies and protein electrophoresis (Western blot) were used to confirm the presence, and aggregation was observed via changes in protein size.

[0074] Bi-FC (Bimolecular Fluorescence Complementation) Og-NSCs or 2D-NSCs were induced to express lentiviruses expressing Venus1-α-synuclein (V1S, N-terminus of α-synuclein) or α-synuclein Venus2 (SV2, C-terminus of α-synuclein), and aggregated α-synuclein in differentiated dopaminergic neurons for 25 days was analyzed by GFP.

[0075] In vivo α-synuclein transmission to transplanted grafts Female Sprague-Dawley rats (225–250 g) were cultured with 2×10 IgG-transfected AAV expressing human hα-synuclein (AAV2-CMV-hα-synuclein, 2×10 13 Og-NSCs (1000 genome copies) and PFFs (10 μg) were injected into the striatum to induce expression and aggregation. Anterior-posterior (AP), -0; mediolateral (ML), -3.0; dorsoventral (DV), -5.0. Two weeks later, Og-NSCs and 2D-NSCs were transplanted into both sides of the striatum, respectively. One month after transplantation, the transfer of α-synuclein to the transplanted cells was analyzed by immunohistochemistry (α-synuclein and p129-α-synuclein).

[0076] Two-photon imaging of GCaMP6-expressing neurons in explants GCaMP6 (Addgene #40753) was produced under the control of the synapsin promoter (pSyn-GCaMP6) and used to propagate in vitro cultures. 2 ml / 6 cm dish or 200 μl / well (24-well plate) and 10 6 Transduction units (TU / ml, 60-70 ng / ml) were used for each transduction reaction. Packaging and production of AAV2-CMV-hα-synuclein were performed at the Korea Institute of Science and Technology (Seoul).

[0077] Og-NSCs at passage 3 were transduced with lentivirus (pSyn-GCaMP6) 3 days before transplantation. The cells were then transplanted into four wild-type SD rats, and the rats were analyzed 1 month after transplantation. Two-photon imaging was performed using a commercial microscope system (SP-5, Leica, Germany) equipped with a Ti:sapphire femtosecond laser (Chameleon Vision, Coherent Inc., USA) with a tunable wavelength of 680–1018 nm, a repetition rate of 80 MHz, and a pulse width of 140 fs.

[0078] For in vivo brain imaging, a single GRIN lens (NEM-100-25-10-860-S-1.0p-ST, GRINTECH GmbH) with a diameter of 1.0 mm and a length of 9.20 mm was used. Under gas anesthesia, the rat was mounted on a rat head holder with the surgically exposed brain facing upward. The GRIN lens was fixed to an aluminum plate through a hole in the plate, and the plate was translated to insert the brain from above. A 10× dry objective lens (Leica HC PL FLUOTAR 10.0×0.30) was placed close to one end of the GRIN lens and coupled to the excitation laser of the microscope system. The excitation wavelength was set to 900 nm for two-photon excitation of GCaMP6. Two-photon imaging was performed by scanning the excitation laser over the brain. The imaging field of view (FOV) and imaging speed were 387.50 μm × 387.50 μm with 512 × 512 pixels and 9.03 frames / s, respectively. Brain emission was collected by a Grin lens and coupled to the microscope system by an objective lens. The microscope system had four detection channels (Ch1: 430-480 nm, Ch2: 500-550 nm, Ch3: 565-605 nm and Ch4: 625-675 nm), and GCaMP6 fluorescence was collected in the second channel (Ch2). The excitation laser power was 58.08 mw.

[0079] Calcium imaging analysis The medium was treated with Fluo3-AM for 1 hour, allowing the cells to absorb Fluo3-AM, and then washed with PBS three times, so that no fluorescence remained in the medium. While observing the fluorescence with a confocal microscope, the fluorescence intensity was taken at intervals of 1 to 3 seconds, and the ROI was measured in each cell at each time frame to confirm that the fluorescence intensity had changed. If necessary, the cells were gated by FACS.

[0080] Experimental Results Preparation of midbrain-type organoids from human embryonic stem cells Conventional differentiation techniques based on two-dimensional 2D culture do not represent the three-dimensional complex circuitry of the actual brain in vivo. Only the development of protocols based on three-dimensional generation can represent the tissue characteristics of the actual brain. Therefore, the research team first prepared 3D midbrain-type organoids in vivo. In the early stages of development to successfully prepare midbrain-type organoids, ZO-1 and N-cadherin were expressed together with stem cell markers PLZF+ and Sox2+ (Figures 7E and 7F). Anterior embryonic brain marker (OTX2) and ventral VM hypoplasia markers (FOXA2 and LMX1A) were expressed together with general neural stem cell markers Nestin and Sox2 (Figures 7G-7I). When development was further induced, the neuronal marker MAP2 was expressed as were the proliferation markers Ki67+ and SOX2+ in other layers, more specifically, the structures specifically expressed in PCNA+ (proliferative ventricular zone VZ), MASH1+ (VZ, intermediate zone (IZ) and mantle zone (MZ)) and NURR1+ cells (IZ and MZ), respectively, as in the brain layers of the living body (Figures 7L and 7M). Characteristically, in the IZ and MZ, the representative midbrain-specific factors FOXA2+, LMX1A+ and NURR1+ cells were expressed together with the dopaminergic neuron marker TH (tyrosine hydroxylase), confirming that these were true midbrain-type dopaminergic neurons (Figures 7N, 7O and 7P).

[0081] Isolation of mesencephalic neural stem cells (Og-NSCs) from mesencephalic organoids We have developed a technique to isolate and culture organoid-derived midbrain-type neural stem cells (Og-NSCs) as a more evolved form of neural stem cells when used as a cell therapy for Parkinson's disease. In previous studies, attempts were made to extract neural stem cells from organoids on days 10 to 35 of development, but the efficiency was not high. It was thought that it would be possible to ensure an appropriate amount of cells by increasing the rate of neural stem cells in the organoids, and the protocol was modified in an effort to increase the amount of cells.

[0082] (1) Since the amount of stem cell population is automatically reduced when differentiation is continuously induced, the terminal development differentiation protocol performed from day 10 was stopped to improve the direction of proliferation. (2) From day 17, it was modified by adding bFGF, which can specifically increase neural stem cells. (3) The proliferation of midbrain-specific neural stem cells was induced by extending the treatment period of midbrain-specific factors (SHH / purmorphamine / CHIR999021) (from day 1 to day 18), i.e., extending the process of midbrain patterning. (4) Different from the conventional method, the FGF8b treatment period was started from day 7 (Figure 8A).

[0083] By controlling such detailed time divisions, it is possible to reduce the occurrence of the hypothalamus (sunthalamic), which is prone to contamination during induction of the midbrain, and significantly increase the expression of EN1, one of the specific markers (Figure 8). By applying these various modifications, growth and culture were performed in a 2D environment on day 18 to induce the generation of midbrain-type organoids. Human vitronectin-coated plates were cultured in bFGF-supplemented hN2 medium. After isolation, the cells contained 84-97% organoid-derived neural stem cells (Og-NSCs). It was confirmed that neural stem cell markers SOX2 and nestin were expressed, and FOXA2 and LMX1A were expressed as OTX2 midbrain-type markers, which are very important for the initial securing of dopaminergic neuron characteristics (Figures 1B and 1C). By confirming the expression of PAX2 and PAX5 factors around the neural stem cells, it was confirmed that they had developed into true midbrain-type cells (Figure 1B). Through the expression of midbrain-specific markers, such as FOXA2+ and LMX1A+ (Figure 12), it was observed that organoid-derived midbrain-type neural stem cells (Og-NSCs) could be expanded while faithfully maintaining their characteristics during secondary culture (Figure 1D). The inventors attempted to prepare VM-type NSCs in 2D hESC culture. Treatment with medium conditioned by VM-like astrocytes (astrocyte-conditioned medium, ACM) is important for cell survival and midbrain marker expression during cell passage (Figure 9A). By enriching the NSC population described above through ACM treatment and modification, the inventors were also able to prepare FOXA2+ / LMX1A+VM-NSCs, which could expand the differentiation of hESCs in conventional 2D culture (Figure 9).

[0084] Organoid-derived mesencephalic neural stem cells (Og-NSCs) can be differentiated into fully-fledged dopaminergic neurons that fully express mesencephalic markers through a terminal differentiation process Through the terminal differentiation process, mesencephalic Og-NSCs can be efficiently differentiated into complete dopaminergic neurons (Figures 1E and 1F). Og-NSC-derived dopaminergic neurons simultaneously expressed mesencephalic markers FOXA2 (95%), LMX1A (96%), NURR1 (91%) and EN1 (86%) along with the dopamine neuron marker TH. Meanwhile, in the conventional 2D culture environment, low mesencephalic factor expression of about 44-61% was shown (Figures 9E, 9F and 10). Furthermore, this organoid-derived mesencephalic neural stem cell isolation protocol is applicable to various human embryonic stem cells and induced pluripotent stem cells (Figures 1G and 11). The success rate of 111 out of 117 experiments performed with 8 human pluripotent stem cells (3 hESCs and 5 hiPSCs) was remarkably high. On the other hand, the 2D method was much more difficult to apply, resulting in a recorded success rate of 28 out of 63 attempts (Figure 1H).

[0085] The H9 hESC line, which shows the highest midbrain-specific factor expression, was mainly used throughout this study. This is because the protocol developed from organoids is very stable and only a small amount seems to undergo the process of cell death during the general procedures, e.g., cell isolation, proliferation and differentiation. This is in contrast to the 2D method, which showed a significant rate of cell death during the procedure. In the actual culture, the analysis of ethidium heterodimer stained dead cells (Figure 1I) and cleaved caspase 3+ dead cells (Figure 1J), as well as the analysis of annexin+ / PI+ dead cells via FACS analysis after cell isolation, showed a relatively low number of stable results (Figure 1K). Senescent cells (pre-apoptotic stage), represented by β-galactosidase+ cells, were also significantly less represented in Og-NSC cultures (Figure 1L). Overall, the newly secured protocol can secure midbrain-type neurons more stably compared to the existing protocol.

[0086] Og-NSC cultured cells can be used as a platform cell for new drug development Og-NSCs can be patterned into midbrain type and differentiated into complete dopaminergic neurons after differentiation, and can maintain the properties for more than 5 passages (Figures 1D, 12A and 12B). Arithmetically, 7,260 vials (9,075 culture dishes) of Og-NSCs can be secured from one culture dish (Figure 12A). In addition, the cells can be stored in nitrogen tanks without losing their function (Figure 12C). As a result, the cells have been actually used by a major pharmaceutical company (Chong Kun Dang Pharm., Seoul, KOREA) for development of new drug candidates for Parkinson's disease (Figure 13). In collaboration with the pharmaceutical company (Chong Kun Dang Pharm., Seoul, KOREA), the scalability and storage of Og-NSC culture system was subjected to bulk screening of candidate chemicals to develop PD drugs using mDA neurons from hESC (H9) and PD-hiPSC (PD-ips1) cell lines (Figure 13).

[0087] Undifferentiated Og-NSCs fully express appropriate midbrain-type neural stem cell markers (Figs. 1B, 1C, 14A, 14E, and 14F). Before differentiation, the cells do not express any differentiated neuron / DA neuron markers (MAP2, TH) (Fig. 14B and C). After inducing terminal differentiation, the expression of proliferation marker Ki67+ is reduced, and morphological changes, such as neurite luminescence, occur as neuronal characteristics (Fig. 14A-C). In the actual developmental stage of midbrain-type neural stem cells, the specific marker NURR1 begins to be expressed at the progenitor cell stage and continues to be expressed until after differentiation (from the second day of differentiation to the terminal differentiation stage) (Fig. 14D). In fact, according to the biological rhythm in midbrain development, FOXA2 and LMX1A continue to be expressed, and after differentiation, the expression of LMX1A+ showed a slight tendency to decrease (Fig. 14E and F). NURR1, FOXA2 and LMX1A, key markers of midbrain-type cells, were fully expressed in terminally differentiated dopaminergic neurons (Figures 1E-1G). These findings collectively indicate that in vitro NSC differentiation recapitulates physiological mDA neuron generation in the VM and may be useful as an in vitro model to study extant human mDA neuron development.

[0088] Analysis of transcriptional regulatory properties of Og-NSCs using bulk and single-cell RNA sequencing To analyze the molecular biological transcriptional regulation of Og-NSCs, RNA sequencing (RNA-seq) analysis was performed. Organoid-derived midbrain-type neural stem cells (Og-NSCs) and neural stem cells (2D-NSCs) generated by conventional differentiation methods were compared and analyzed for differences in transcriptional regulators with existing human fetal and adult brain tissues (Carithers, LJ, Ardlie, K., Barcus, M., Branton, PA, Britton, A., Buia, SA, Compton, CC, DeLuca, DS, Peter-Demchok, J., Gelfand, ET, et al. (2015). A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreserv Biobank 13, 311-319.; Jo, J., Xiao, Y., Sun, AX, Cukuroglu, E., Tran, HD, Goke, J., Tan, ZY, Saw, TY, Tan, CP, Lokman, H., et al. al.(2016).Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons.Cell Stem Cell 19, 248-257.) According to previous reports (Jo,J., Xiao,Y., Sun,AX, Cukuroglu,E., Tran,HD, Goke,J., Tan,ZY, Saw,TY, Tan,CP, Lokman,H.,et al.(2016).Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons.Cell Stem Cell 19, 248-257.), PCA (principal component analysis) and Spearman correlation analysis showed that midbrain-type organoids were significantly similar to human fetal brain (Figures 2A and 2B).Og-NSCs resemble midbrain-type organoids and maintain these characteristics (Spearman's correlation coefficient: 0.79-0.97). In addition, Og-NSCs resemble the actual fetal midbrain (0.70-0.85), so it appears that Og-NSCs derived from actual neural stem cells maintain their characteristics even during the process of isolation and subculture.

[0089] To confirm the properties of each individual cell in the neural stem cell colonies, single-cell RNA-seq was performed (Og-NSCs: 13,793 cells analyzed in total; 2D-NSCs: 12,166 cells analyzed. On average, 3.8 × 10 RNA-seq was performed per cell. 5 (There were 1,000 normalized reads, and 2,227 genes were detected in each individual cell). On average, 3.8 × 10 5There were 1,000 normalized reads, and 2,227 genes were detected in each individual cell. As expected, about 99.7% of Og-NSC and conventional 2D-NSC cells expressed neural stem cell markers NESTIN, VIMENTIN, NCAM1, SOX2, NOTCH1, and MUSASHI1 (Figure 15A). Totipotent cell markers POU5F1, NANOG, and KLF4 were expressed in only 0.09%, 0.45%, and 0.91% of Og-NSC cells, and even in cells expressing this marker, the expression level of the marker was insignificant (mean unique molecular identifier (UMI) was <0.005) (Figure 15B). Although mostly neural stem cells, conventional 2D-NSCs showed slightly higher expression relative to totipotent cells (0.19%, 2.69%, and 1.24%, respectively, with mean UMI of <0.031). Since there are no cells expressing the three markers simultaneously in both Og-NSCs and 2D-NSCs, this indicates that only neural stem cells can be isolated and cultured. Through FACS analysis, the expression of TRA-1-60 and SSEA-4 was confirmed to be almost absent (Figure 15C). Previously, it was analyzed that the number of senescent cells (pre-apoptotic stage) was also significantly reduced in Og-NSC cultures (Figure 1L), and the number of cells expressing apoptotic genes was also very low (Figure 15D).Notably, a much lower percentage of Og-NSC cells expressed p16 / INK4a compared to 2D-NSC cells, which is consistent with the increased expression of p16 / INK4a in the brain (Molofsky, AV, Slutsky, SG, Joseph, NM, He, S., Pardal, R., Krishnamurthy, J., Sharpless, NE, and Morrison, SJ(2006).Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing.Nature 443, 448-452.; Nishino, J., Kim, I., Chada, K., and Morrison, SJ(2008).Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression.Cell 135, 227-239.) and other organizations ((Sousa-Victor, P., Gutarra, S., Garcia-Prat, L., Rodriguez-Ubreva, J., Ortet, L., Ruiz-Bonilla, V., Jardi, M., Ballestar, E., Gonzalez, S., Serrano, AL, et al. al.(2014).Geriatric muscle stem cells switch reversible quiescence into senescence.Nature 506, 316-321.; Wang, J., Lu, 124, 3237-3240.) are important features for cellular aging / senescence and reduced stem cell repair capacity.

[0090] The Og-NSC cell population analyzed by t-SNE (t-distributed stochastic neighbor embedding) analysis can be classified into three clusters (Figures 2C-2E). To confirm the characteristics of each cell cluster, GO (Gene Ontology) analysis of the genes with increased expression was performed (UMI>1, log2FC>0.5, P<0.05) (Figure 2F). Cluster 3 accounts for 25% (Og-NSC) and 12% (2D-NSC) (Figure 2D). Genetic analysis showed that this is a cell population that is already destined to become neurons and contains a significant number of differentiation factors. In the case of the genes overexpressed in cluster 1, a large number of genes important for the development of the substantia nigra (SN), where dopamine neurons are generated, are expressed (ENO3, RSPO2, FGF9, LDHA, NR4A2, INA, LMX1A, OTX2, HSPA5, SYNGR3, RAD1, UCHL1, EN1, NDUFS3, and SEC16A). Therefore, it can be said that cluster 1 is the most complete cell population patterned into the midbrain. In particular, 71% of Og-NSC cells and 13% of existing 2D-NSC cells belong to cluster 1. The genetic analysis also showed that Og-NSC cultures have much more midbrain-type patterning and that it is possible to stably secure the cell population without contamination by totipotent cells and without apoptosis.

[0091] We analyzed the bulk and single-cell RNA-seq data (Og-NSCs vs. 2D-NSCs) in more detail via GO and KEGG analysis (Figures 2H and 2I). According to the sequencing data of the two methods, the gene group that is relatively more frequently expressed in Og-NSCs (compared to 2D-NSCs) is the cell adhesion and ECM gene group, which highlights its importance in maintaining stem cell development and function. The expression of this gene group, which is highly expressed in both methods, was studied by unsupervised hierarchical clustering (Figure 2J). Special functions were also described (Table 5).

[0092] [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5]

[0093] In addition, the gene groups that are highly expressed specifically in the Og-NSC cell population are "SN development" or "negative regulation of cell death" in terms of midbrain patterning (Figure 2I). In the analysis of single-cell RNA-seq analysis, in particular, gene groups related to mitochondrial biological functions were found to be roughly regulated in the Og-NSC group (mitochondrial function, ER and protein folding, and autophagy). This can be emphasized as mitochondria are closely related to the organs that are typically affected in the context of neurodegenerative diseases that are closely related to cell aging and death. In the KEGG analysis through this data, correlations can also be inferred, as they are ranked as top changes in "Parkinson's disease", "Huntington's disease" and "Alzheimer's disease", which are representatives of neurodegenerative diseases (Figure 2I).

[0094] Mitochondrial function is crucial in the differentiation of human embryonic stem cells and induced pluripotent stem cells. In particular, neural stem cell mitochondria are known to be crucial for the progression and pathogenesis of neurodegenerative diseases. Mitochondrial genes, including those related to mitochondrial biogenesis and dynamics, were all modulated in Og-NSCs in two different bulk and single RNA-seq analyses compared to cells derived by conventional methods (Figure 3A). Analogous to gene analysis, the Og-NSC cell population could be analyzed with a mitotimer, and it was found that the Og-NSC cell population was much healthier and more functionally superior than conventional 2D-NSCs (Figure 3B). The health and functional superiority of Og-NSCs is also seen by mitochondrial ROS analysis (Mitosox, Figure 3C). In addition, the Og-NSC group also had a high mitochondrial membrane potential, showing superiority in all aspects (JC-1, Figure 3D). In addition to improved mitochondrial metabolism and antioxidant capacity, mDA neurons differentiated from Og-NSCs showed more resistance to apoptosis (Figure 3E) and neurite degeneration (Figure 3F) induced by various mitochondrial toxins than those derived from 2D-NSCs.

[0095] Dopaminergic neurons (mDA neurons) differentiated from Og-NSCs coexist with astrocytes, resulting in improved neuronal function and maturation Transcriptional regulation of genes indeed shows early changes before the shape of the cell population changes. For example, in the actual gene analysis (in differentially expressed genes (DEGs)), the changes seen in neural stem cells are those seen at the embryonic neural stem cell stage. In bulk RNA-seq analysis, genes related to neuronal maturation were highly expressed in Og-NSC (vs. 2D-NSC) cells (Figures 2H and 3G). In gene expression profiles, when compared to their 2D counterparts, midbrain-type dopamine neurons induced from Og-NSCs showed a more mature morphology after neuronal differentiation (Figures 3H and 3J), a more mature morphology in terms of synaptogenesis (Figures 3I and 3K), and action potential-induced Ca2+ expression (Figures 3I and 3K). 2+Dynamics (Figures 3L-3O) and presynaptic dopamine neuron function (Figure 3P) were assessed by depolarization-induced dopamine secretion.

[0096] In all current hPSC-mDA differentiation protocols, mDA neurons are generated without astrocyte differentiation. Similarly, no astrocyte differentiation was found in cultured 2D-NSCs (Figures 3R and 3S). Interestingly, 17% of cells in a subpopulation of O-NSC cluster 1 (a midbrain-type SN-generating cell population, a cluster with higher SN development gene expression) shared the signature of high expression of genes related to glial development (EIF2B5, MT3, PLP1, CDK6, SCL1A3, HES1, HES5, and SOX8) (Figure 3Q). This indicates that Og-NSC cultures contain a VM (SN)-type glial precursor population. Consistently, some cells in Og-NSC cultures expressed CD44 (Figure 3S), which is specifically found in neurogenic progenitors that differentiate into astrocytes during peripheral differentiation (Figure 3R). These cells express CD44, a marker of astrocyte precursor cells (Figure 3R), and are therefore expected to differentiate into astrocytes during their terminal differentiation (Figure 3S).Similar to the actual pattern of midbrain development, mDA neurons are seen to be generated together with GFAP+ astrocytes (Figure 3S).

[0097] Thus, mDA neurons were generated together with GFAP+ astrocytes in differentiation cultures, as in the midbrain in vivo (Figure 3S). In addition to the general neurotrophic action of astrocytes, VM astrocytes are known to induce specific dopaminotrophic functions superior to astrocytes in other brain regions.

[0098] Considering the cytokine secretion ability of astrocytes based on previous reports, it can be expected that astrocytes have a positive effect when dopaminergic neurons are generated. Based on this information, as shown in Figures 1E-1L and 3E-3P, neighboring astrocytes can induce neurotrophic support for mDA neuron maturation, survival, presynaptic function, and midbrain-specific factor expression.

[0099] Dopaminergic neurons differentiated from Og-NSCs are less prone to α-synuclein oligolysis and pathological propagation. To prevent α-synucleinopathy present in the original patient's brain from spreading to transplanted cells, and for the long-term success of cell therapy for Parkinson's disease, it is important to ensure that cells used as cell therapy agents (to be transplanted) are resistant to α-synuclein propagation. Pathological propagation of toxic α-synuclein is associated with cell-to-cell transfer of α-synuclein, and α-synuclein aggregation is also associated with transfer to transplanted cells. To measure the cell-to-cell transfer ability of α-synuclein, Og-NSCs and 2D-NSCs were analyzed using a dual chamber system (Choi, YR, Cha, SH, Kang, SJ, Kim, JB, Jou, I, and Park, SM (2018b). Prion-like Propagation of alpha-Synuclein Is Regulated by the FcgammaRIIB-SHP-1 / 2 Signaling Pathway in Neurons. Cell reports 22, 136-148), respectively. GFP-labeled α-synuclein (a protein overexpressed in SH-SY5Y neuronal cells) was placed in the chamber, cultured Og-NSC (2D-NSC)-derived neurons were placed under the chamber, and uptake and spread were observed after protein transport (Figure 4A). As a result, it was observed that the fluorescence intensity of GFP-labeled α-synuclein was significantly lower in Og-NSC-derived neurons (Figure 4B).

[0100] In addition to α-synuclein transfer, another important issue, pathological propagation of α-synuclein to transplanted cells, was analyzed by toxic α-synuclein aggregates. The extent of aggregation was compared and analyzed in the presence of increased amounts of α-synuclein in cells or in conditions where α-synuclein was introduced exogenously (exogenous α-synuclein fibril seeds).

[0101] Og-NSC and 2D-NSC cell populations were infected with lentivirus overexpressing α-synuclein, oxidative stress was induced after differentiation of dopaminergic neurons, and toxic α-synuclein aggregation and propagation were analyzed. Serine 129 phosphorylated α-synuclein (p129-α-synuclein), which may be toxic α-synuclein, or GFP+α-synuclein migration was observed to be less in Og-NSC (Figure 4C). Accordingly, toxic α-synuclein aggregation was also observed to be less in differentiated Og-NSC cell populations (Figure 4D, left). In addition, toxic α-synuclein aggregation was observed by preparing conditions in which α-synuclein was introduced from the outside (exogenous α-synuclein fibril seeds) by injecting α-synuclein fibrils (PFFs). As a result, it was found that toxic α-synuclein aggregation was higher in conventional 2D-NSCs (Figure 4D, right side) and that toxic α-synuclein aggregation under various conditions was less in Og-NSC cell populations. Next, toxic α-synuclein aggregation was observed by a Bi-FC (bi-molecular fluorescence complementation) system. This system is a system that observes α-synuclein by showing strong fluorescence when amino (N)-terminal (VIS) or carboxy (C)-terminal (SV2) Venus fragments are expressed and aggregated, respectively (Figures 4E and 4F). Oxidative stress and mitochondrial destruction are known to induce protein misfolding and aggregation of α-synuclein. The relative resistance of Og-NSC-derived dopaminergic neurons to α-synucleinopathies can be attributed to lower oxidative and mitochondrial stress (Figures 3B-3F). In addition, the inclusion of astrocytes in the differentiated Og-NSC cell population can also reduce toxic α-synuclein aggregation to the original function of astrocytes, thus appearing to contribute to the reduction of α-synucleinopathies. Overall, Og-NSC-derived neurons have a relative inhibition of toxic α-synuclein propagation, which was confirmed by studies of α-synuclein inside and outside the cells.

[0102] Finally, Og-NSCs or 2D-NSCs were transplanted into brain tissue in vivo to observe the propagation and aggregation of α-synuclein in a real brain environment. Human-specific α-synuclein overexpressing AAV virus and PFFs were injected into the striatum of rats to induce Parkinson's disease caused by α-synucleinopathy. Two weeks later, Og-NSCs and 2D-NSCs were transplanted into an animal striatum model to observe the differences in the in vivo brain environment. Analysis of the transplanted tissue after one month showed that in a severe α-synucleinopathy environment, there were almost no surviving dopaminergic neurons at the conventional 2D-NSC-derived transplant site (Figure 4G, lower panel), Lewy bodies co-expressing α-synuclein+ and p129-α-synuclein+ were observed, and neurites were hardly differentiated. Therefore, it was shown that conventional cell populations are not suitable as cell therapy agents. On the other hand, in the case of the newly developed Og-NSC cell population-derived transplant sites, the neuronal shape was much healthier and there was no severe neurite degeneration (Figure 4G, upper panel). Furthermore, less toxic α-synuclein+ (p129-α-synuclein+) aggregation was observed in various neuronal sites. In the case of Parkinson's disease patients, even after transplantation of cell therapy, the propagation of patient-derived α-synuclein to transplanted cells (host vs. graft α-synuclein propagation) is a significant issue in the survival of patients (11-16 years after transplantation). In the case of animal models, α-synuclein propagation and aggregation are observed in a much earlier period of about 1 month. Although not fully reflecting the patient's brain environment, the results of in vitro and in vivo assays indicate that Og-NSC-derived cells are more resistant to toxic α-synuclein propagation and aggregation.

[0103] Og-NSC transplantation provides healthy dopaminergic neurons in Parkinson's disease animal models Finally, the potential of Og-NSC-derived cell populations as cell therapeutic agents was observed after transplantation into an animal model system in which Parkinson's disease was induced with 6-OHDA (6-hydroxydopamine). Recently, genes that can predict the success of human embryonic stem cell-derived cells after transplantation have been studied. As expected, single-cell RNA-seq analysis found that this group of genes was relatively highly expressed in the newly developed Og-NSC cell population (compared to conventional 2D cell populations) (Figure 5A). Synaptic plasticity of transplanted dopaminergic neurons is very important for cell survival and future transplant success. To analyze the function as neurons, GFP fluorescently labeled GCaMP6 (a calcium indicator protein that emits green fluorescence upon binding Ca++) was expressed in the Og-NSC cell population and then transplanted into the brain striatum. Neuronal function was observed by two-photon endoscopy one month after transplantation without any special stimulation of the neurons (Figure 5B, upper). Spontaneous neuronal signaling was observed in the transplanted Og-NSC cells. Ca 2+The transient response (ΔF / F) showed a neuronal action potential frequency of 2-5 Hz (Figure 5B, lower), which is similar to dopaminergic neurons originally arising in the SNpc (substantia nigra pars compacta) of brain tissue. To further confirm the synaptic plasticity of transplanted Og-NSC cells, Og-NSC cells were prepared from a human embryonic stem cell population expressing a gene with GFP bound to delta-like canonical Notch ligand 1 (Dll1, pDll1-GFP-hESC). Since these are fluorescently expressed only in differentiated neurons, only cells expressing fluorescence were analyzed after cell transplantation into Parkinson's disease model animals. After one and a half months, patch clamp analysis observed action potentials (Figure 5C) and spontaneous excitatory postsynaptic currents (sESPCs) (Figure 5D) in transplanted GFP-expressing neurons. The synaptic plasticity of the transplanted neurons was not significantly different from that of the contralateral non-lesioned normal cells (Figures 5E and 5F), indicating that the neurons had functionally intact morphology even after transplantation of Og-NSCs. To find out whether the transplanted dopaminergic neurons were fully mature and had intact synaptic functions, such as dopamine secretion, we measured the dopamine transporter-mediated dopamine transport in the grafted neurons. 18 F]FP-CIT PET scans. As a result, the striatum of Parkinson's disease animals showed low dopamine uptake (2% of the intact hemisphere), which relatively recovered to 40% of normal levels 5 months after transplantation of Og-NSC cell populations (Figures 5G and 5H).

[0104] Og-NSC cell populations were transplanted into Parkinson's disease animal models and behavioral studies were performed. As a result, amphetamine-induced rotational intention analysis showed the recuperative effect of the transfer. At about 6 months after transplantation, the behavioral recovery (rotation score) of 11 out of 14 animals was >50% of the pre-transplantation level. In the case of 8 animals observed 6 months after transplantation, all animals showed results of >79% (Figure 6A). In transplanted animals, the recuperative effect was also shown in the step test (Figure 6B) and the cylinder test (Figure 6C).

[0105] Six months after transplantation of Og-NSCs into the animal model, the results were analyzed. Healthy dopaminergic neuronal tissue was confirmed at the transplant site (graft volume: 4.50 ± 1.56 mm 3, TH+ cells: 9031±3773 cells, n=8 in six independent transplantation experiments, Fig. 6D-6O). No consistent specific proliferation was observed at the transplantation site. This is the same as the differentiation into Og-NSC-derived dopaminergic neurons in vitro (Fig. 2H and 3G-3I). Notably, the transplanted dopaminergic neurons maturely formed synapses with cells in the original brain tissue and extended normal neurites (Fig. 6D). Although midbrain-specific factors are very important for the survival and maturation of dopaminergic neurons, it is known that their expression is not well maintained after transplantation. For this reason, most existing papers did not show the expression of all midbrain-type factors in the tissue after transplantation, but only showed images of the maximum FOXA2 / TH+ expressing cells. However, the transplanted cell population derived from Og-NSC developed by the protocol of the present invention expresses all important midbrain-specific factors. Even 6 months after transplantation, 96.7% (3,106 / 3,196, FOXA2), 93.8% (3,338 / 3,549, LMX1A), 95.0% (3,496 / 3,678, NURR1), and 91.5% (2,989 / 3,274, EN1) of the major midbrain-specific factors were co-expressed with TH+, a marker of dopaminergic neurons (8 animals, Figure 6E-6I). In particular, GIRK2, a marker of A9 substantia nigra dopaminergic neurons, was expressed (Figure 6J). As a main characteristic of A9 substantia nigra dopaminergic neurons, the transplanted dopaminergic neurons had a mature morphology that extended neurites in multiple directions (Figure 6E-6G and 6H, lower drawings and Figure 6P), and the original brain tissue cells and mature neurites were also extended (Figure 6D). Human GFAP (hGFAP)-expressing astrocytes clustered around transplanted dopaminergic neurons (Figure 6K), indicating that transplanted Og-NSC-derived astrocytes help dopaminergic neurons form synapses by extending neurites and aid in cell maturation, consistent with previous astrocyte co-transplants that showed similar effects.To confirm the effect in primates, we transplanted Og-NSC-derived cell populations into the striatum of two adult Philippine monkeys, and one month later, mature dopaminergic neurons were identified that co-expressed key midbrain-type markers FOXA2 and NURR1 (Figure 6P).

[0106] Consideration Cultured organoids can be applied to tissue development and human disease modeling research, and can also be a source of donor transplantation in regenerative medicine. However, transplantation of brain organoids into deep brain regions is not feasible without damage to the host brain tissue, and transplantation of brain organoids is not applicable to the treatment of brain disorders. Furthermore, the therapeutic outcome of transplanted brain organoids should be able to establish new neural circuits, in which the self-organized structures in the transplanted organoids interact with the host brain in a very precise manner. In contrast, transplanted organoids from other tissues (liver, intestine, kidney, pancreas, etc.) can induce therapeutic functions as isolated functional units (liver buds, pancreatic islets, renal nephrons, etc.) after transplantation. Thus, although organoid transplantation may have the potential to treat other extra-CNS disorders, direct transplantation of brain organoids to treat brain disorders is impractical.

[0107] All tissue development is achieved through a sequential generation process, proliferation of tissue-specific stem / progenitor cells and differentiation into tissue-specific cells. Cultured tissue-specific stem / progenitor cells can provide donor cells for regenerative medicine, as well as a bioassay platform for developmental studies and drug screening. However, derivation of NSC cultures with proper VM patterning from hPSCs was not achieved in previous studies. The inventors realized that the difficulty in preparing VM-specific NSC cultures was due to the instability of VM region characteristics during culture. As the maintenance of VM-specific marker expression is highly sensitive to cell density, it is easily lost during the cell isolation and replacement process required for NSC preparation (Figure 9A).

[0108] Therefore, hPSC-mDA neuron protocols were developed with very high cell densities or specific plate coating materials such as Lamin 511 or 111 (Biolamina, LN-511, LN-111). Various efforts using different cell dissociation conditions (Actinase, Collagenase, Ca++, Mg++ free HBSS), cell survival cytokines (TGFβ, Doxycycline, cAMP, Ascorbic acid, Y27632), open epigenetic conditions (5-Azacytidine, VPA, TSA), chemicals inducing β-estradiol or DAPT (Notch inhibitor) failed to solve the problem.

[0109] In a recent study (Song, JJ, Oh, SM, Kwon, OC, Wulansari, N, Lee, HS, Chang, MY, Lee, E, Sun, W, Lee, SE, Chang, S, et al. (2018). Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model. The Journal of clinical investigation 128, 463-482.), the inventors observed that factors secreted from cultured astrocytes, particularly those derived from VM tissue, exerted potent trophic effects to promote cell survival and midbrain-specific factor expression in primary NSC and mDA neuron cultures.

[0110] Therefore, the 2D-NSC culture protocol used in this study can be developed through treatment with conditioned medium prepared from cultured astrocytes (ACM) (Figure 9). However, the derivation of 2D-NSC culture still had the aforementioned stability and reproducibility problems. In contrast, NSCs with stable VM marker expression were easily isolated and cultured from rodent embryonic VM tissue, and upon stimulation, human VM-specific NSCs were isolated from hPSC-derived midbrain-like organoids, with architectural structures and regional characteristics in an environment similar to the physiological structure of the embryonic brain.

[0111] Organoid-based formulations have had great success in terms of stability of VM patterning in NSC cultures with faithful midbrain-specific marker expression, and general culture stability with very low levels of apoptosis, senescence, oxidative and mitochondrial stress. Another notable observation was that Og-NSCs contain an astrocyte progenitor population with a VM-specific gene expression profile that differentiates into astrocytes mixed with mDA neurons. In contrast, mDA neuron differentiation is induced without astrocyte differentiation in all existing methods for hPSC-mDA differentiation, and thus, there was no astroglia in the differentiated mDA neuron cultures. Thus, in the absence of astroglial support, neural maturation and function could not be expected to be identical to differentiated mDA neurons in their in vivo counterparts. In fact, poor maturation and function have been proposed to be a significant drawback in the utility of mDA neurons differentiated from hPSCs in in vitro disease modeling and therapy. In contrast, under trophic support by mixed astrocytes, Og-NSC-derived mDA neurons exhibited improved synaptic maturation, functionality, resistance to toxic insults, and improved settings of long-term midbrain-specific factor expression in vivo and after transplantation. All these properties of Og-NSCs ultimately contribute to reproducible and superior long-term therapeutic efficacy after transplantation. In addition, the inventors have demonstrated that organoid-derived NSCs are a scalable cell source required for the preparation of donor cells for therapy, as well as a bioassay platform for drug screening, developmental studies, and disease modeling.

[0112] Based on the present invention, the organoid-based method can become a general next-generation strategy to prepare tissue-specific stem / progenitor cells with strong therapeutic potential for not only CNS but also non-CNS disorders.

[0113] In other words, there is no doubt that the cells of organoid are healthier than those of two-dimensional culture, and cell therapy can obtain superior results.Because the characteristics of brain tissue make it undesirable to directly transplant organoid in the form of "lump", the present invention can be said to be the most suitable model for cell therapy of the nervous system.

[0114] Example 2: Differentiation of human pluripotent stem cells into cerebral cortical neural stem cells using cerebral cortical organoids [Experimental Procedure] Culture of human pluripotent stem cells (hESC...

Claims

1. 1. A method for obtaining large amounts of terminally differentiated cells, comprising: 1) Proliferating and culturing human pluripotent stem cells to prepare 3D organoids; 2) culturing the 3D organoids in a 2D plate with vitronectin; 3) patterning and chopping the cultured 3D organoids; 4) culturing and expanding stem cells or progenitor cells in the chopped organoids and inducing differentiation of the stem cells or progenitor cells to obtain large amounts of terminally differentiated cells; Including, The organoid is a midbrain organoid; The method, wherein the terminally differentiated cells are midbrain dopamine neurons and / or astrocytes.

2. The method of claim 1 , wherein the human pluripotent stem cells and stem cells are cultured using vitronectin.

3. The method of claim 1 or 2, wherein the stem cells are ectodermal stem cells.

4. The method according to any one of claims 1 to 3, wherein the precursor cells are cerebral astrocyte precursor cells or mesencephalic astrocyte precursor cells.

Citation Information

Patent Citations

  • Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells for Use in Drug Screening and Treatment of Amyotrophic Lateral Sclerosis (als)

    JP2016535248A

  • Method for producing dopaminergic neurons

    WO2015020234A1

  • Methods for generating and using organoids and cells thereof

    WO2019032680A1